

Unclassified

ENV/JM/MONO(2016)33/REV1

Organisation de Coopération et de Développement Économiques
Organisation for Economic Co-operation and Development

22-Aug-2017

English - Or. English

**ENVIRONMENT DIRECTORATE
JOINT MEETING OF THE CHEMICALS COMMITTEE AND
THE WORKING PARTY ON CHEMICALS, PESTICIDES AND BIOTECHNOLOGY**

Overview of the set of OECD Genetic Toxicology Test Guidelines and updates performed in 2014-2015

**Series on Testing & Assessment
No. 238 - 2nd edition**

JT03418020

Complete document available on OLIS in its original format

This document, as well as any data and map included herein, are without prejudice to the status of or sovereignty over any territory, to the delimitation of international frontiers and boundaries and to the name of any territory, city or area.



ENV/JM/MONO(2016)33/REV1
Unclassified

English - Or. English

OECD Environment, Health and Safety Publications

Series on Testing and Assessment

No. 238

Overview of the set of OECD Genetic Toxicology Test Guidelines and updates performed in 2014-2015

IOMC

INTER-ORGANIZATION PROGRAMME FOR THE SOUND MANAGEMENT OF CHEMICALS

A cooperative agreement among **FAO, ILO, UNDP, UNEP, UNIDO, UNITAR, WHO, World Bank and OECD**

Environment Directorate
ORGANISATION FOR ECONOMIC CO-OPERATION AND DEVELOPMENT
Paris 2017
About the OECD

The Organisation for Economic Co-operation and Development (OECD) is an intergovernmental organisation in which representatives of 35 industrialised countries in North and South America, Europe and the Asia and Pacific region, as well as the European Commission, meet to co-ordinate and harmonise policies, discuss issues of mutual concern, and work together to respond to international problems. Most of the OECD's work is carried out by more than 200 specialised committees and working groups composed of member country delegates. Observers from several countries with special status at the OECD, and from interested international organisations, attend many of the OECD's workshops and other meetings. Committees and working groups are served by the OECD Secretariat, located in Paris, France, which is organised into directorates and divisions.

The Environment, Health and Safety Division publishes free-of-charge documents in twelve different series: **Testing and Assessment; Good Laboratory Practice and Compliance Monitoring; Pesticides; Biocides; Risk Management; Harmonisation of Regulatory Oversight in Biotechnology; Safety of Novel Foods and Feeds; Chemical Accidents; Pollutant Release and Transfer Registers; Emission Scenario Documents; Safety of Manufactured Nanomaterials; and Adverse Outcome Pathways.** More information about the Environment, Health and Safety Programme and EHS publications is available on the OECD's World Wide Web site (www.oecd.org/chemicalsafety/).

This publication was developed in the IOMC context. The contents do not necessarily reflect the views or stated policies of individual IOMC Participating Organizations.

The Inter-Organisation Programme for the Sound Management of Chemicals (IOMC) was established in 1995 following recommendations made by the 1992 UN Conference on Environment and Development to strengthen co-operation and increase international co-ordination in the field of chemical safety. The Participating Organisations are FAO, ILO, UNDP, UNEP, UNIDO, UNITAR, WHO, World Bank and OECD. The purpose of the IOMC is to promote co-ordination of the policies and activities pursued by the Participating Organisations, jointly or separately, to achieve the sound management of chemicals in relation to human health and the environment.

This publication is available electronically, at no charge.

**For this and many other Environment,
Health and Safety publications, consult the OECD's
World Wide Web site (www.oecd.org/ehs)**

or contact:

**OECD Environment Directorate,
Environment, Health and Safety Division
2, rue André-Pascal
75775 Paris cedex 16
France**

Fax : (33-1) 44 30 61 80

E-mail : ehscont@oecd.org

© OECD 2017

Applications for permission to reproduce or translate all or part of this material should be made to: Head of Publications Service, RIGHTS@oecd.org, OECD, 2 rue André-Pascal, 75775 Paris Cedex 16, France

FOREWORD

This document presents an Overview of the set of OECD Genetic Toxicology Test Guidelines (TGs) and updates performed in 2014-2015. The projects for the global update of the Genetic Toxicology TGs and the development of an accompanying document were included in the work plan of the Test Guidelines Programme in 2011. The projects were led by a group of four countries, France, Canada, the US and the Netherlands. The present document gives an account of the update of the set of genetic toxicology TGs which was completed in 2015 and provides at the same time a succinct overview of the TGs for genetic toxicology.

The present document was circulated twice to the Working Group of the National Coordinators of the Test Guidelines Programme (WNT) for review and commenting, in September and December 2015. The resulting comments were addressed and the document subsequently approved by the WNT at its 28th meeting in April 2016. The Joint Meeting of the Chemicals Committee and the Working Party on Chemicals, Pesticides and Biotechnology agreed to declassification of this document on 8 July 2016.

Following an initial publication in July 2016, the document was updated in 2017 with the inclusion of an annex presenting a document developed during the update of the set of Test Guidelines on genotoxicity and supporting the WNT decision to implement revised criteria for the selection of the top concentration in the in vitro mammalian cell assays on genotoxicity (Test Guidelines 473, 476 and 487). The revision was approved by the WNT by written procedure in March 2017 and the Joint Meeting of the Chemicals Committee and the Working Party on Chemicals, Pesticides and Biotechnology agreed to declassification of the updated document on 5 May 2017.

This document is published under the responsibility of the Joint Meeting of the Chemicals Committee and the Working Party on Chemicals, Pesticides and Biotechnology.

**OVERVIEW OF THE SET OF OECD GENETIC TOXICOLOGY TEST GUIDELINES AND
UPDATES PERFORMED IN 2014-2015**

TABLE OF CONTENTS

Overview of the set of OECD Genetic Toxicology Test Guidelines and updates performed in 2014-2015	3
FOREWORD.....	6
OVERVIEW OF THE SET OF OECD GENETIC TOXICOLOGY TEST GUIDELINES AND UPDATES PERFORMED IN 2014-2015.....	7
1 GENERAL INTRODUCTION (PREAMBLE).....	9
1.1 General Background.....	9
1.2 History and Status of TGs.....	10
2 AIM OF GENETIC TOXICOLOGY TESTING.....	12
2.1 Genotoxicity Endpoints.....	12
3 TEST GUIDELINES FOR GENETIC TOXICOLOGY.....	13
3.1 <i>In vitro</i> genetic toxicology tests.....	14
3.1.1 Tests for gene mutations.....	14
3.1.2 Tests for chromosomal abnormalities.....	16
3.2 <i>In vivo</i> genetic toxicology tests.....	18
3.2.1 Tests for gene mutations.....	18
3.2.2 Tests for chromosomal abnormalities.....	18
3.2.3 Tests for Primary DNA Damage.....	20
4 OVERVIEW OF ISSUES ADDRESSED IN THE 2014-2015 REVISION OF THE GENETIC TOXICOLOGY TEST GUIDELINES.....	22
4.1 Issues specific to <i>in vitro</i> TGs.....	22
4.1.1 Cells.....	22
4.1.2 Cytotoxicity and selection of highest concentration for cytotoxic chemicals.....	22
4.1.3 Selection of highest concentration tested for poorly soluble and/or non-cytotoxic chemicals..	24
4.1.4 Treatment duration and sampling time.....	24
4.1.5 Concentration selection and minimum number of test concentrations/cultures.....	25
4.1.6 Metabolic Activation.....	26
4.2 Issues specific to <i>in vivo</i> TGs.....	26
4.2.1 Dose Selection.....	26
4.2.2 Proof of exposure (bioavailability).....	27
4.2.3 Tissue selection, duration of treatment and sampling time.....	28
4.2.4 Combination/integration of tests.....	29
4.2.5 Use of one or both sexes.....	30
4.2.6 Age range of animals.....	31
4.3 Issues common to <i>in vitro</i> and <i>in vivo</i> TGs.....	31
4.3.1 Experimental design and statistical analysis considerations.....	31
4.3.2 Size of samples and statistical power: <i>in vitro</i> tests.....	31

4.3.3	Size of samples and statistical power: in vivo tests	33
4.3.4	Demonstration of laboratory proficiency and establishing an historical control database	34
4.3.5	Concurrent negative and positive controls	35
4.3.6	Data interpretation and criteria for a positive/negative result.....	37
4.3.7	Chemicals that require specific approaches.....	39
4.3.8	Test batteries, weight of the evidence and interpretation of data	39
REFERENCES		40
APPENDIX A. DOCUMENT SUPPORTING THE WNT DECISION TO IMPLEMENT REVISED CRITERIA FOR THE SELECTION OF THE TOP CONCENTRATION IN THE IN VITRO MAMMALIAN CELL ASSAYS ON GENOTOXICITY (TEST GUIDELINES 473, 476 AND 487) - [ENV/JM/TG/RD(2014)20]		52
APPENDIX B. TREATMENT AND SAMPLING TIMES FOR IN VIVO GENETIC TOXICOLOGY TGS IN RODENTS (THE APPLICABLE TGS SHOULD BE CONSULTED FOR MORE DETAILED INFORMATION).....		62
APPENDIX C. COMPILATION OF PUBLISHED NEGATIVE (VEHICLE) CONTROL DATA FOR THE DOMINANT LETHAL TEST.....		63
APPENDIX D. COMPILATION OF PUBLISHED NEGATIVE (VEHICLE) CONTROL DATA FOR THE MOUSE SPERMATOGONIAL CHROMOSOMAL ABERRATION TEST.		65
APPENDIX E. DEFINITIONS		66

1 GENERAL INTRODUCTION (PREAMBLE)

1. An Introduction Document to the OECD Genetic Toxicology Test Guidelines (TGs) was first published in 1987 (OECD, 1987). Following a global update of the Genetic Toxicology TGs, which was completed in 2015, the present Document was written to provide succinct and useful information to individuals unfamiliar with genetic toxicology testing, as well as experienced individuals wishing to obtain an overview of the recent changes that were made to the TGs during the recent round of revisions. It provides: 1) general background and historical information on the OECD genetic toxicology TGs; 2) a brief overview of the important types of genetic damage evaluated by these tests; 3) a description of the retained TGs; and 4) the issues and changes addressed therein during the revision process. It should be noted that the purpose of this Document is different from that of the previous 1987 Introduction Document, in that it is not intended to provide an extensive overview of the field of Genetic Toxicology, or to provide an extensive discussion of the strengths and weaknesses of the tests, or to discuss testing strategies.

1.1 General Background

2. Since the 1980s, the view on the relative importance of the various tests for which a TG exists has changed. Simultaneously, there has been an increase in our knowledge of the mechanisms leading to genetic toxicity, as well as an increase in our experience with the use of the tests. The interpretation of test results has evolved, as has the identification of the critical technical/procedural steps in the different tests. Moreover, it has become clear that tests which detect the types of genetic damage that can be transmitted in mammalian cells should be considered to be the most relevant for evaluating chemicals for their potential to induce mutations.

3. There have also been significant economic changes since the OECD genetic toxicology TGs were first established (1983). The number of newly developed chemicals to be tested has increased; furthermore, regulatory jurisdictions, such as the European Registration, Evaluation, Authorization and Restriction of CHemical regulations (REACH; EC, 2006; ECHA, 2008a,b), require assessment of the toxicity (including genotoxicity) of an unprecedented large number of chemicals already in commerce. Consequently, there is an impetus for testing to become more efficient, and faster; whereas, at the same time, it is recognised that the performance (i.e. sensitivity and specificity) of the tests should not suffer. In addition, most regulatory authorities have increased their commitment to avoid unnecessary use of animals in toxicology testing. For some regulatory genetic toxicology testing strategies the number of required tests has been reduced from several to 3, or even as few as 2, *in vitro* tests. In line with the basic principles of humane animal experimentation (Replacement, Reduction, and Refinement, *i.e.* 3Rs; Russell and Burch, 1959) it has been recommended that *in vitro* tests should be followed up with as few as possible, but scientifically adequate, *in vivo* tests. Regulatory authorities have established various ways to do this, including a prohibition of *in vivo* tests in the European Union (EU) Regulation for cosmetic ingredients (EC, 2009), and the need to submit a testing proposal prior to some vertebrate test specified under REACH (EC, 2006). Importantly, significant reductions in animal use can be accomplished, by the combination of *in vivo* genetic toxicity endpoints, as well as their incorporation into repeated dose toxicity tests, or by reducing the number of animals for concurrent positive controls in *in vivo* genetic toxicology tests, thus reducing the total number of animals used in evaluating a particular test chemical. The 3Rs principles were taken into consideration in the revision of each individual *in vivo* test, and are thus reflected in the final recommendations in each *in vivo* TG. Because regulatory authorities may implement the 3Rs in different ways, neither the individual TGs, nor this Document, list specific regional requirements.

4. At its 22nd meeting in March 2010, the OECD Workgroup of National Coordinators for Test Guidelines (WNT) formed an Expert Workgroup that would review all the genetic toxicology TGs and make decisions to delete or update the various TGs, and to develop new TGs. Subsequently, taking advantage of experience with the tests, the TG revisions were made, which reflect increased knowledge

concerning the features of the various tests and the technical conduct of the tests. In addition, the revision process provided an opportunity to harmonise, as appropriate, the recommendations across all of the genetic toxicology TGs under revision. This harmonisation led to a common approach concerning the features and conduct of the various tests.

1.2 History and Status of TGs

5. The history and current status of the different TGs is summarised in Table 1. Since the last round of TG revisions in 1997, new TGs have been adopted: TG 487 (*in vitro* mammalian cell micronucleus test) in 2010; TG 488 (transgenic rodent somatic and germ cell gene mutation assays) in 2011; TG 489 (*in vivo* mammalian alkaline comet assay) in 2014; and finally, TG 490 (*in vitro* mammalian cell gene mutation assays using the thymidine kinase (*TK*) gene [Mouse Lymphoma Assay (MLA) and TK6 test] approved in 2015. Because of the acceptance of a new TG (TG 490) that includes both the MLA and TK6 tests, TG 476 was revised and updated, and now includes only the *in vitro* mammalian cell gene mutation tests using the hypoxanthine guanine phosphoribosyl transferase (*Hprt*) locus and xanthine-guanine phosphoribosyl transferase transgene (*xprt*) gene.

6. A decision to delete some TGs was made based on the observation that these tests are rarely used in the various legislative jurisdictions, that some basic core tests have been demonstrated as being robust and sufficient based on many years of use, or on the availability of newer tests showing a better performance for the same endpoint. Moreover, the assays conducted in mammalian cells are preferred to those in yeasts, fungi or insects because they are considered more relevant to mammalian biology. TGs that were deleted include: TG 477 (sex-linked recessive lethal test in *Drosophila melanogaster*); TG 480 (*Saccharomyces cerevisiae*, gene mutation test); TG 481 (*Saccharomyces cerevisiae*, mitotic recombination assay); TG 482 (DNA damage and repair, Unscheduled DNA synthesis test in mammalian cells *in vitro*); and, TG 484 (mouse spot test). In addition, TG 479 (*in vitro* sister chromatid exchange test for mammalian cells) was deleted because of a lack of understanding of the mechanism(s) of action of the effect detected by the test. Once approved for deletion, a TG is in effect for 18 months. During the 18 months, under the Mutual Acceptance of Data (MAD), assays that were planned before may continue to be conducted and the results should be accepted by regulatory agencies. After the 18 months, results that were previously generated, prior to the effective deletion date shall continue to be accepted, but no new test should be initiated using the deleted test guideline.

7. Thus, the tests described in the deleted TGs should not be used for new testing, and are no longer a part of the set of OECD recommended tests. However, data previously generated from these deleted TGs can still be used in regulatory decisions. Therefore, the deleted TGs are available on the OECD public website <http://www.oecd.org/env/ehs/testing/oecdguidelinesforthetestingofchemicals.htm> - bottom section ("Test Guidelines that have been deleted or replaced by updated versions"), because it may be useful to consult these TGs in the context of the assessment of chemicals based on old study reports.

8. In addition, it was recognised that two tests have limitations that result in their being less widely used and less favoured by some regulatory authorities than in the past. These include TG 485, (the mouse heritable translocation assay which requires 500 first generation males per dose level) and TG 486 [the unscheduled DNA synthesis (UDS) test with mammalian liver cells *in vivo*]. Although both of these tests fulfill most of the criteria for deletion, the decision was made to neither delete, nor update, these TGs because they were still viewed as having utility by some regulatory agencies.

9. A decision was made not to update TG 471 (bacterial reverse mutation test) during this round of revisions.

Table 1: Current status of the Test Guidelines for genetic toxicology

TG	Title	Adopted	Revised	Deleted	Reference
Recently Revised					
473	<i>In vitro</i> mammalian chromosomal aberration test	1983	1997 / 2014		OECD, 2014a
474	Mammalian erythrocyte micronucleus test	1983	1997 / 2014		OECD, 2014b
475	Mammalian bone marrow chromosomal aberration test	1984	1997 / 2014		OECD, 2014c
476	<i>In vitro</i> mammalian cell gene mutation test using the <i>Hprt</i> and <i>xprt</i> genes	1984	1997 / 2015		OECD, 2015a
478	Rodent dominant lethal test	1984	2015		OECD, 2015b
483	Mammalian spermatogonial chromosomal aberration test	1986	1997/2015		OECD, 2015c
Recently Adopted					
487	<i>In vitro</i> mammalian cell micronucleus test	2010	2014		OECD, 2014d
488	Transgenic rodent somatic and germ cell gene mutation assays	2011	2013		OECD, 2013
489	<i>In vivo</i> mammalian alkaline comet assay	2014			OECD, 2014e
490	<i>In vitro</i> gene mutation assays using the <i>TK</i> gene	2015			OECD, 2014d
Archived/Deleted					
472	Genetic toxicology: <i>Escherichia coli</i> , Reverse Assay	1983		1997	
477	Sex-linked recessive lethal test in <i>Drosophila melanogaster</i>	1984		2014	
479	<i>In vitro</i> sister chromatid exchange assay in mammalian cells	1986		2014	
480	<i>Saccharomyces cerevisiae</i> , gene mutation assay	1986		2014	
481	<i>Saccharomyces cerevisiae</i> , mitotic recombination assay	1986		2014	
482	DNA damage and repair, unscheduled DNA synthesis in mammalian cells <i>in vitro</i>	1986		2014	
484	Mouse spot test	1986		2014	
Retained, but not revised					
471	Bacterial reverse mutation assay	1983	1997		OECD, 1997a
485	Mouse heritable translocation assay	1986			OECD, 1986
486	Unscheduled DNA synthesis (UDS) test with mammalian liver cells <i>in vivo</i>	1997			OECD, 1997b

¹After the revision, TG 476 is only used for the mammalian cell gene mutation test using the *Hprt* or *xprt* locus

2 AIM OF GENETIC TOXICOLOGY TESTING

10. The purpose of genotoxicity testing is to identify chemicals that can cause genetic alterations in somatic and/or germ cells, and to use this information in regulatory decisions. Compared to most other types of toxicity, genetic alterations may result in effects that are manifested only after long periods following exposure. Furthermore, the deleterious effect can be caused by DNA damage that occurs in a single cell at low exposures. Rather than destroying that cell, the genetic alteration can result in a phenotype that not only persists, but can be amplified, as the cell divides, creating an expanding group of abnormal cells within a tissue or organ. Genetic alterations in somatic cells may cause cancer if they affect the function of specific genes (*i.e.* proto-oncogenes, tumour suppressor genes and/or DNA damage response genes). Mutations in somatic and germ cells are also involved in a variety of other (non-cancer) genetic diseases. Accumulation of DNA damage in somatic cells has been related to some degenerative conditions, such as accelerated aging, immune dysfunction, cardiovascular and neurodegenerative diseases (Erickson, 2010; Hoeijmakers *et al.*, 2009; Slatter and Gennery, 2010; De Flora and Izzotti, 2007; Frank, 2010). DNA damage in germ cells is associated with spontaneous abortions, infertility, malformation, or heritable mutations in the offspring and/or subsequent generations resulting in genetic diseases, e.g. Down syndrome, sickle cell anemia, hemophilia and cystic fibrosis (Yauk *et al.* 2015).

2.1 Genotoxicity Endpoints

11. Two types of genetic toxicology studies are considered (in order of importance): 1) those measuring direct, irreversible damage to the DNA that is transmissible to the next cell generation, (*i.e.* mutagenicity) and 2) those measuring early, potentially reversible effects to DNA, or the effect of mechanisms involved in the preservation of the integrity of the genome (genotoxicity). It is recognised that there are a number of different specific definitions for mutagenicity and genotoxicity that are used in different geographic regions and by different regulatory authorities. For the purpose of this Document, the use of working definitions for mutagenicity and genotoxicity has been proposed. These definitions are presented below.

12. **Mutagenicity** is a subset of genotoxicity. Mutagenicity results in events that alter the DNA and/or chromosomal number or structure that are irreversible and, therefore, capable of being passed to subsequent cell generations if they are not lethal to the cell in which they occur, or, if they occur in germ cells, to the offspring. Thus, mutations include the following: 1) changes in a single base pairs; partial, single or multiple genes; or chromosomes; 2) breaks in chromosomes that result in the stable (transmissible) deletion, duplication or rearrangement of chromosome segments; 3) a change (gain or loss) in chromosome number (*i.e.* aneuploidy) resulting in cells that have not an exact multiple of the haploid number; and, 4) DNA changes resulting from mitotic recombination. Positive results in mutagenicity tests can be caused by test chemicals that do not act directly on DNA. Examples are aneuploidy caused by topoisomerase inhibitors, or gene mutations caused by metabolic inhibition of nucleotide synthesis. There is an extensive literature on elucidation of these mechanisms by follow-up testing as part of risk assessment strategies that are beyond the scope of this guidance.

13. **Genotoxicity** is a broader term. It includes mutagenicity (described above), and it also includes DNA damage which may be mutagenic, but may also be reversed by DNA repair or other cellular processes, and, thus, which may or may not result in permanent alterations in the structure or information content in a surviving cell or its progeny. Accordingly, tests for genotoxicity also include those tests that evaluate induced damage to DNA (but not direct evidence of mutation) via effects such as unscheduled DNA synthesis (UDS), DNA strand breaks (e.g. comet assay) and DNA adduct formation, *i.e.* primary DNA damage tests (see Section 3).

3 TEST GUIDELINES FOR GENETIC TOXICOLOGY

14. A full evaluation of a chemical's ability to induce the possible types of genetic damage involved in adverse human health outcomes (cancer, non-cancer diseases involving somatic cell mutation, and heritable disease involving germ cell mutation) includes tests that can detect gene mutation, structural chromosomal damage and aneuploidy. To adequately cover all the genetic endpoints, one must use multiple tests (*i.e.* a test battery), because no individual test can provide information on all endpoints. Complete assessment of mutagenic potential through the detection of gene mutations, structural chromosomal aberrations, and numerical chromosomal abnormalities can be achieved in a variety of ways. However, the selection of: 1) which tests to use, 2) how to combine them into test batteries, 3) whether to use them for initial screening or to follow up previously generated results, and 4) how to interpret the hazard identified (or not), or to make decisions about further testing or regulatory action, is beyond the purview of the OECD TGs and this document. Recommended batteries of tests are described in other regional or international regulatory documents for various types of chemicals (*e.g.* Cimino, 2006a and b; Eastmond *et al.*, 2009).

15. There are tests that detect primary DNA damage (*i.e.* the first in the chain of events leading to a mutation), but not the consequences of this genetic damage. The endpoint measured in these tests does not always lead to a mutation, a change that can be passed on to subsequent generations (of cells or organisms). The DNA damage measured in the comet assay, or the unscheduled DNA synthesis test, may lead to cell death, or it may initiate DNA repair, which can return the DNA either to its original state or result in mutation. When evaluating the mutagenic potential of a test chemical, more weight should be given to the measurement of permanent DNA changes (*i.e.* mutations) than to DNA damage events that are reversible. However, tests that detect primary DNA damage can be useful for: 1) preliminary screening; 2) as part of *in vivo* follow up of *in vitro* positive results; 3) for mechanistic studies, *e.g.* for the detection of oxidative DNA damage; 4) as an exposure biomarker demonstrating that the test chemical, or its metabolic or reactive products, have reached a target tissue and can damage the DNA; and 5) the investigation of the mode of action of carcinogens in target tissues.

16. The information and recommendations provided in the TGs have been developed specifically for the routine evaluation of test chemicals, in particular for hazard identification. It should be recognised that the recommendations in each of the TGs and reflected in this Document are, therefore, specific for hazard identification. When a test is being used for more detailed experimentation, or for other regulatory purposes (other than hazard identification), modification(s) of the protocol may be necessary. For instance, if the goal is to conduct a more detailed dose response evaluation, perhaps at low doses/concentrations to assess whether there is a no observed-effect level, or to better define a point of departure for quantitative risk assessment, or to understand the response at particular levels of exposure, it is likely that a greater number of test concentrations/doses would be required, and/or a different strategy for concentration/dose selection (than indicated in the TGs), and/or increasing the power of the study (than indicated in the TGs; *e.g.* by scoring more cells) would be needed. If the goal is to evaluate whether a chemical that is a mutagen and a carcinogen is inducing specific tumors via a mutagenic mode of action, it would be desirable to tailor the concentration/dose selection and possibly the length of exposure and timing of sampling to optimally address the question(s) being investigated for that specific chemical. There are a number of references that provide additional information for designing experiments that go beyond simple hazard identification (Cao *et al.*, 2014; Gollapudi *et al.*, 2013; Johnson *et al.*, 2014; MacGregor *et al.*, 2015a; MacGregor *et al.*, 2015b; Moore *et al.*, 2008; Parsons *et al.*, 2013; and Manjanantha *et al.*, 2015).

17. The individual TGs provide specific information describing the tests and the detailed recommendations for their conduct. The tests are briefly discussed below. This section is divided into *in vitro* and *in vivo* tests, and further divided based on the principal genetic endpoint detected by the specific test.

3.1 *In vitro* genetic toxicology tests

3.1.1 Tests for gene mutations

18. **TG 471: Bacterial Reverse Mutation Test.** The bacterial reverse mutation test (commonly called the “Ames test”) identifies chemicals that induce gene mutations (*i.e.* both base-pair substitutions and frameshift mutations resulting from small insertions and deletions). This test uses specific strains of two species of bacteria, *Salmonella typhimurium* and *Escherichia coli*. Each strain contains identified mutations in an amino acid biosynthesis gene (*i.e.* histidine [His] or tryptophan [Trp], respectively) as the reporter gene. Those mutations prevent bacterial growth in the absence of the amino acid in the growth medium. Exposure to mutagens may induce a mutation (a reversion) that will restore the wild type DNA sequence, or the wild type phenotype, and the functional capability of the bacteria to synthesise the essential amino acid, and thus, to grow on medium without the required amino acid. Cells in which this function-restoring mutation (reversion) has occurred are called revertants and for the test method, bacterial colonies are counted. Consequently, the Ames test is termed a “reverse mutation test”.

19. There is a panel of specific strains that are used for the bacterial reverse mutation test, which are each sensitive to a different mechanism of mutation (*e.g.* base substitution at GC pairs, base substitution at AT pairs, or a single base insertion or deletion). A positive result in any one strain is considered relevant, and positive results in additional strains do not necessarily increase the level of confidence in the mutagenic response. The strains that can be reverted by the test chemical, and therefore, the types of mutation(s) induced by the test chemical, may provide information on the chemical’s mechanism of action.

20. An advantage of the bacterial reverse mutation test is the relatively large number of cells exposed (about 10^8) with a background mutant frequency that is both low and stable enough to allow a large range of response between the background and the highest induced mutant frequencies usually detected. This combination of wide range and stable background allows for relatively sensitive and reliable detection of chemicals that induce a weak response.

21. *S. typhimurium* and *E. coli* are prokaryotic bacteria that differ from eukaryotic/mammalian cells in factors such as cellular uptake, metabolism, chromosome structure and DNA repair processes. As such, they have some limitations in reflecting the effects in mammalian species including humans. There have been developments to automate the test and to minimise the amount of test chemical required (Claxton *et al.*, 2001; Fluckiger-Isler *et al.*, 2004; Sui *et al.*, 2009). While widely used for screening, the miniaturised versions of the Ames test have not been universally accepted as replacements for standard regulatory testing.

22. **TG 476: *In vitro* Mammalian Cell Gene Mutation Tests Using the *Hprt* or *xprt* genes.** These *in vitro* mammalian cell gene mutation tests identify chemicals that induce gene mutations at the *Hprt* (hypoxanthine-guanine phosphoribosyl transferase) or *xprt* (xanthine-guanine phosphoribosyl transferase) reporter gene. This test is a forward mutation test because the mutation inactivates the function of the gene product rather than reversing a previous inactivating mutation. Gene mutations are evaluated as mutant colonies that can grow in medium containing the selective agent 6-thioguanine, a metabolic poison which allows only cells deficient in HPRT to grow and form colonies. Because the *Hprt* gene is on the X-chromosome in humans and rodents, only one copy of the *Hprt* gene is active per cell. Thus, a mutation involving only the single active *Hprt* gene will result in a cell with no functional HPRT enzyme. The test can be performed using a variety of established cell lines. The most commonly used cells for the HPRT test include the CHO, CHL and V79 lines of Chinese hamster cells, L5178Y mouse lymphoma cells, and TK6 human lymphoblastoid cells. The non-autosomal location of the *Hprt* gene (X-chromosome) allows the detection of point mutations, insertions and deletions of varying lengths.

23. For the XPRT assay, the bacterial *gpt* transgene that codes for the XPRT enzyme, a bacterial analogue of the mammalian HPRT protein enzyme, is used. The only cells recommended in TG 476 for the XPRT assay are AS52 cells (derived from CHO cells) containing the bacterial *gpt* transgene (and from which the *Hprt* gene was deleted). The autosomal location of the *gpt* locus allows the detection of certain genetic events, such as large deletions and loss of heterozygosity via inter-allelic recombination, not readily detected in the HPRT test because such events may be lethal due to the lack of homologous genes (Honma et al., 1997).

24. Both tests involve treating cells with the test chemical, followed by an incubation period that provides sufficient time (termed the expression time) for the newly induced mutants to lose their functional HPRT or GPT enzyme. The cell population is cloned in the presence and absence of the selective agent 6-thioguanine for the enumeration of mutant cells and the measurement of cloning efficiency, respectively, in order to calculate a mutant frequency. This mutant selection can be performed either using Petri dishes (for monolayer cultures) or microtiter culture plates (for suspension cell cultures). The soft agar cloning method has also been used successfully for the HPRT assay in L5178Y mouse lymphoma cells (Moore and Clive, 1982).

25. The cell density in mutant selection culture plates should be limited in order to avoid metabolic co-operation (sharing of HPRT enzyme) between mutant and non-mutant cells, which would alter mutant selection. This is particularly important for cells growing in monolayer such as cultures of V79 or CHO cells (COM 2000), but is less of an issue for cells growing in suspension.

26. **TG 490: *In vitro* Mammalian Cell Gene Mutation Tests Using The Thymidine Kinase Gene.** This new TG describes two distinct assays that identify chemicals that cause gene mutations at the thymidine kinase (*TK*) reporter gene. The two assays use two specific *TK* heterozygous cell lines: L5178Y *TK*^{+/-}3.7.2C cells for the mouse lymphoma assay (MLA) and TK6 (*TK*^{+/-}) cells for the TK6 assay; these are forward mutation assays. The mouse lymphoma assay (MLA) and TK6 assay using the *TK* locus were originally described in TG 476. Since the last revision of TG 476, the MLA Expert Workgroup of the International Workshop for Genotoxicity Testing (IWGT) has developed internationally harmonised recommendations for assay acceptance criteria and data interpretation for the MLA (Moore *et al.* 2003, 2006) and this new TG was written to accommodate these recommendations. While the MLA has been widely used for regulatory purposes, the TK6 assay has been used much less frequently. It should be noted that in spite of the similarity between the endpoints, the two cell lines are not interchangeable, and there may be a valid preference for one over the other for a particular regulatory program. For instance, the validation of the MLA demonstrated its appropriateness for detecting not only gene mutation, but also the ability of a test chemical to induce structural chromosomal mutation [International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH, 2011)].

27. The autosomal and heterozygous nature of the *TK* gene in the two cell lines enables the detection of cells deficient in the enzyme TK following mutation from *TK*^{+/-} to *TK*^{-/-}. This deficiency can result from genetic events that are compatible with cell survival while they affect the *TK* gene. Genetic events detected using the *TK* locus include both gene mutations (base substitutions, frameshift mutations, small deletions) and chromosomal damage (large deletions, chromosomal rearrangements and mitotic recombination). The latter events are expressed as loss of heterozygosity (LOH), which is a common genetic change of tumor suppressor genes in human tumorigenesis.

28. *TK* mutants include normal growing and slow growing mutants. These are recognised as “large colony” and “small colony” mutants in the MLA, and as “early appearing colony” and “late appearing colony” mutants in the TK6 assay. Normal growing and slow growing mutants are scored simultaneously and differentiated by size and shape in the MLA. Normal growing and slow growing mutants are scored at

different incubation times in the TK6 assay. Scoring of slow growing colonies in the TK6 assay requires cell refeeding with the selective agent and growth media (Liber *et al.*, 1989). Normal growing and slow growing mutants must be enumerated as separate mutant frequencies. Normal growing colonies are considered indicative (but not exclusively predictive) of chemicals inducing point and other small-scale mutations; whereas, slow growing colonies are considered indicative of chemicals that induce chromosomal damage (Moore *et al.*, 2015; Wang *et al.*, 2009). Slow growing colonies consist of cells that have suffered damage impacting genes adjacent to *TK*. Their doubling time is prolonged and, thus, the size of the colony is smaller than for a normal growing one (Amundson and Liber, 1992; Moore *et al.*, 2015).

29. The test involves treating cells with the test chemical. After a sufficient expression time for the newly induced mutants to lose their functional TK enzyme, the cell population is cloned in the presence and absence of the selective agent triflurothymidine for the enumeration of mutant cells and the measurement of cloning efficiency, respectively, in order to calculate a mutant frequency. For the MLA, this mutant selection can be performed using soft agar cloning medium in Petri dishes or liquid medium in microwell culture plates. The TK6 assay is generally conducted using microwell culture plates.

3.1.2 Tests for chromosomal abnormalities

30. There are basically two types of endpoints that can be used to determine if a chemical can cause chromosomal damage and/or aneuploidy; chromosomal aberrations and micronuclei. Most cells containing chromosomal aberrations are not viable when, for example, the deficiency comprises essential gene(s) and, thus, they are not transmitted to daughter cells. Micronuclei are visualised in cells following the first cell division, but are not retained in all subsequent generations. Thus, most events detected in the chromosomal aberration and micronucleus tests are not mutations *per se*. Nevertheless, based on many genetic studies of the chromosomal basis of heritable genetic effects in humans and other species, it can be assumed that chemicals able to induce chromosomal aberrations and micronuclei in those tests are also able to induce transmissible chromosome mutations, *e.g.* reciprocal translocations, stable translocations and aneuploidy (Yauk *et al.*, 2015).

31. **TG 473: *in vitro* Mammalian Chromosomal Aberration Test.** The *in vitro* chromosomal aberration test identifies chemicals that induce structural chromosomal aberrations (breaks, deletions and rearrangements). In cultures of established cell lines [*e.g.* CHO, V79, Chinese Hamster Lung (CHL), TK6] or primary cell cultures, including human or other mammalian peripheral blood lymphocytes The cells used should be selected on the basis of growth ability in culture, stability of the karyotype (including chromosome number) and spontaneous frequency of chromosomal aberrations. At the present time, the available data do not allow firm recommendations to be made, but suggest it is important, when evaluating chemical hazards, to consider the *p53* status, genetic (karyotype) stability, DNA repair capacity and origin (rodent *versus* human) of the cells chosen for testing. The users of this test are, thus, encouraged to consider the influence of these and other cell characteristics on the performance of a cell line in detecting the induction of chromosomal aberrations, as knowledge evolves in this area.

32. Structural chromosomal aberrations may be of two types, chromosome or chromatid, depending on the mechanism of action; the chromatid-type is most often observed. Most chromosomal aberrations are observed only in metaphases of the first or second mitotic cell division after treatment, because most cells containing these aberrations are lost in subsequent cell divisions, they do not result in mutations *per se*. Chemicals may be active in particular phases of the cell cycle and, thus, give a particular pattern of chromatid versus chromosome aberrations. That is, a G2-active chemical is likely to induce chromatid aberrations at the first mitosis, but many of these events will be converted into chromosome aberrations in the second mitosis. Furthermore, damage induced pre-S-phase will appear as chromosome aberrations but damage induced post-S-phase will result in chromatid aberrations in the first mitosis. When cells are exposed to chemicals during the entire cell cycle, it is likely that both chromatid and chromosome aberrations will be observed. Individual cells are viewed by microscope and the information on the types of

chromosomal aberrations observed in each cell is recorded. Chromosomal aberrations occur if DNA strand breaks are misrepaired. This repair system theoretically involves removal of a few nucleotides to allow somewhat inaccurate alignment of the two ends for rejoining followed by addition of nucleotides to fill in gaps.

33. There is extensive literature suggesting that fluorescence in situ hybridisation (FISH), or chromosome painting, can provide additional (mechanistic) information including detection of aneuploids through enhanced visualisation of translocations that are not readily visible in the standard chromosomal aberration test. However, the Expert Group did not incorporate recommendations regarding use of these techniques in any of the Test Guidelines for chromosomal aberrations (TG 473, TG 475, and TG 483) during update of the Test Guidelines.

34. Polyploidy (including endoreduplication) could arise in chromosome aberration assays *in vitro*. While aneuploids can induce polyploidy, polyploidy alone does not indicate aneuploid potential, and can simply indicate cell cycle perturbation or cytotoxicity. This test is not designed to measure aneuploidy. An *in vitro* micronucleus test would be recommended for the detection of aneuploidy.

35. **TG 487: *in vitro* Mammalian Cell Micronucleus Test.** The *in vitro* micronucleus test identifies chemicals that induce chromosomal breaks and aneuploidy. Micronuclei are formed when either a chromosome fragment or an intact chromosome is unable to migrate to a mitotic pole during the anaphase stage of cell division and is not incorporated into the daughter nuclei. The test, thus, detects chromosomal breaks (caused by clastogens) or numerical chromosomal abnormalities or chromosome loss (caused by aneuploids). In order to differentiate clastogens (micronuclei without centromeres/kinetochores) from aneuploids (micronuclei with centromeres/kinetochores), it is necessary to use FISH and centromere or kinetochore staining.

36. The test can be conducted using cultured primary human, or other mammalian peripheral blood lymphocytes, and a number of cell lines such as CHO, V79, CHL, L5178Y and TK6. There are other cell lines that have been used for the micronucleus assay (*e.g.* HT29, Caco-2, HepaRG, HepG2 and primary Syrian Hamster Embryo cells), but these have not been extensively validated, and the TG recommends that they be used only if they can be demonstrated to perform according to the described requirements. The cells used are selected on the basis of their ability to grow well in culture, stability of their karyotype (including chromosome number), and spontaneous frequency of micronuclei. At the present time, the available data do not allow firm recommendations to be made, but suggest it is important, when evaluating chemical hazards to consider the *p53* status, genetic (karyotype) stability, DNA repair capacity and origin (rodent *versus* human) of the cells chosen for testing. The users of this test are, thus, encouraged to consider the influence of these and other cell characteristics on the performance of a cell line in detecting the induction of micronuclei, as knowledge evolves in this area.

37. The scoring of micronuclei is generally conducted in the first interphase after the first division of cells following test chemical exposure. Cytochalasin B (cytoB) can be used to block cytoplasm division/cytokinesis and generate binucleate cells during or after test chemical exposure. This may be desirable, because it can be used to measure cell proliferation and allows the scoring of micronuclei in dividing cells only. The use of cytochalasin B is mandatory for mixed cell cultures, such as whole blood cultures, in order to identify the dividing target cell population; but for cell lines the test can be conducted either with or without cytochalasin B; however, potential interactions between the test chemical and cytochalasin B should be noted. It should be noted that when using L5278Y cells there may be problems with conducting the test, and, therefore, the MN test should be performed without cytochalasin B.

38. Automated systems that can measure micronucleated cell frequencies include, but are not limited to, flow cytometers (Avlasevich, *et al.*, (2011), image analysis platforms (Doherty *et al.* 2011; Seager *et al.*, 2014), and laser scanning cytometers (Styles *et al.*, 2001).

39. The *in vitro* micronucleus test has been shown to be as sensitive as the chromosomal aberration test for the detection of clastogens, and has the additional advantage of detecting aneugens (Corvi *et al.*, 2008). However, the *in vitro* micronucleus test does not allow identification of translocations and other complex chromosomal rearrangements that can be visualised in the chromosomal aberration assay, and which may provide additional mechanistic information.

3.2 *In vivo* genetic toxicology tests

3.2.1 *Tests for gene mutations*

40. For the *in vivo* gene mutations tests, mutations are measured in transgenic “reporter” genes that generally are not expressed *in situ*; however, both “reporter” genes and endogenous, expressed genes are assumed to be mutated through similar molecular mechanisms (OECD, 2009). Positive selection systems have been developed to select, visualise, and enumerate the clones/colonies resulting from mutant cells.

41. **TG 488: Transgenic Rodent Somatic and Germ Cell Gene Mutation Assays.** The transgenic rodent gene mutation test identifies chemicals that induce gene mutations in transgenic reporter genes in somatic and male germ cells. The test uses transgenic rats or mice that contain multiple copies of chromosomally integrated phage or plasmid shuttle vectors, which harbour the transgenic reporter genes in each cell of the body, including germ cells. Therefore, mutagenicity can be detected in virtually any tissues of an animal that yield a sufficient amount of DNA, including specific site of contact tissues and germ cells. The reporter genes are used for detection of gene mutations and/or small deletions and rearrangements resulting in DNA size changes (the latter specifically in the *lacZ* plasmid and *Spi* test models) induced *in vivo* by the test chemicals (OECD, 2009, OECD, 2011; OECD, 2009). Briefly, genomic DNA is extracted from tissues, transgenes are recovered from genomic DNA, and transfected into a bacterial host deficient for the reporter gene. The mutant frequency is measured using specific selection systems. The transgenes are genetically neutral in the animals, *i.e.* their presence or alteration has no functional consequence to the animals that harbour them. These transgenes respond to treatment in the same way as endogenous genes in rats or mice with a similar genetic background, especially with regard to the detection of base pair substitutions, frameshift mutations, and small deletions and insertions (OECD, 2009). These tests, therefore, circumvent many of the limitations associated with the study of *in vivo* gene mutation in endogenous genes (*e.g.* limited tissues suitable for analysis that can be used to readily enumerate mutant cells). Because the target genes are functionally neutral, mutations can accumulate over time allowing increased sensitivity for detection of mutations when tissues receive repeated administrations of the test chemical. A 28-day treatment is recommended for exposing both somatic and germline tissues.

42. DNA sequencing of mutants is not required, but it is often helpful to confirm that the mutational spectra, or type of mutations seen following treatment, are different from those found in the untreated animal/tissue, to calculate the frequency of the different specific types of mutations, and to provide mechanistic data. DNA sequencing is also used to estimate the amount of clonal expansion of the originally mutated cell to more accurately estimate the actual mutation frequency by adjusting the frequency of mutants detected by positive selection.

3.2.2 *Tests for chromosomal abnormalities*

43. As described in Section 3.1.2, there are two types of chromosome damage endpoints (chromosomal aberrations and micronuclei). Based on many genetic studies of the chromosomal basis of

heritable genetic effects in humans and other species, it can be assumed that chemicals able to induce chromosomal aberrations and micronuclei in those tests are also able to induce transmissible chromosome mutations (e.g. reciprocal translocations, stable translocations and aneuploidy) in humans.

44. **TG 474: Mammalian Erythrocyte Micronucleus Test.** The mammalian erythrocyte micronucleus test identifies chemicals that induce micronuclei in erythroblasts sampled from bone marrow (usually measured in immature erythrocytes) or peripheral blood (usually measured in reticulocytes) of animals. Normally rodents are used, but other species (e.g. dogs, primates, humans) can be studied when justified. When a bone marrow erythroblast develops into an immature erythrocyte (also referred to as a polychromatic erythrocyte, or reticulocyte) and then migrates into the peripheral blood, the main nucleus is extruded. Subsequently, any micronuclei that have been formed may remain behind in the cytoplasm. Thus, detection of micronuclei is facilitated in erythrocytes because they lack a main nucleus.

45. Micronuclei may originate from acentric chromosomes, lagging chromosome fragments or whole chromosomes, and, thus, the test has the potential to detect both clastogens and aneugens. The use of FISH and centromere, kinetochore, or alpha-satellite DNA staining can provide additional mechanistic information, and help differentiate clastogens (resulting in micronuclei without centromeres) from aneugens (resulting in micronuclei with centromeres). Automated systems that can measure micronucleus frequencies include, but are not limited to, flow cytometers for erythrocytes (Torous *et al.*, 2000; De Boeck *et al.*, 2005; Dertinger *et al.*, 2011), image analysis platforms (Doherty *et al.*, 2011), and laser scanning cytometers (Styles *et al.*, 2001).

46. Micronuclei can be measured in other tissues, provided that the cells have proliferated before tissue collection and can be properly sampled (Hayashi *et al.*, 2007; Uno 2015a and b). However, this TG is restricted to measurement of effects in the bone marrow that are subsequently detected in the bone marrow *per se* or in the peripheral blood because of the lack of validation of tests applied to other tissues. These limitations restrict the usefulness of the micronucleus test for the detection of chemicals targeting specific organs.

47. **TG 475: Mammalian Bone Marrow Chromosomal Aberration Test.** The mammalian bone marrow chromosomal aberration test identifies chemicals that induce structural chromosomal aberrations in bone marrow cells. While rodents are usually used, other species may in some cases, be appropriate, if scientifically justified. Structural chromosomal aberrations may be of two types, chromosome- or chromatid-type depending on the mechanism of action. The chromatid-type is more often observed. Chromosomal aberrations are observed only in metaphase of the first or second mitotic cell division because cells containing aberrations are usually lost in subsequent cell divisions.

48. Although chromosomal aberrations can potentially be measured in other tissues, TG 475 describes detection of effects in bone marrow cells only. Because of this tissue limitation, the test may not provide useful information for chemicals targeting specific organs nor for reactive direct acting chemicals that should be tested at a site of contact. Cell information on the various types of chromosomal aberrations is visualised in individual cells using microscopy.

49. The standard design of this test is not optimised for the detection of aneuploidy. Polyploidy (including endoreduplication) could arise in chromosomal aberration tests *in vivo*. Although increased incidence of polyploidy may be seen as an indication for numerical chromosomal abnormalities, an increase in polyploidy *per se* does not indicate aneugenic potential; rather, it may simply indicate cell cycle perturbation. Because of the nature of the damage, it can only be detected within days of its occurrence.

50. **TG 478: Rodent Dominant Lethal Test.** The rodent dominant lethal test identifies chemicals that induce genetic damage causing embryonic or fetal death resulting from inherited dominant lethal

mutations induced in germ cells of an exposed parent, usually male rats or mice (Bateman, 1984; Generoso and Piegorsch, 1993) or, predominantly, in the zygote after fertilisation (Marchetti *et al.*, 2004). Usually male rats are treated and mated to a number of untreated virgin females sufficient to permit the detection of at least a doubling in the dominant lethal frequency; occasionally, females are treated; however, females appear less suitable in a system where fertilisation of the eggs is essential and where embryonic death is evaluated (Green *et al.*, 1985).

51. Dominant lethality is generally a consequence of structural and/or numerical chromosomal aberrations, but gene mutations and toxic effects cannot be excluded. Because it requires a large number of animals, this test is rarely used. While death of a fetus is the event detected, the dominant lethal test does not necessarily assess a biological endpoint that reflects a potential health risk to future generations, it does represent an adverse health outcome for the mother. Furthermore, chemicals that cause dominant lethality also cause F₁ congenital malformations (*i.e.* the viable equivalent of dominant lethality; Anderson *et al.*, 1998), and the majority of chemicals that are positive in the dominant lethal test also are positive in the heritable translocation test (TG 485) and specific locus test (Yauk *et al.*, 2015) which do measure heritable mutations *per se*. Accordingly, the dominant lethal test is also predictive of mutational events that can affect the offspring.

52. **TG 483: Mammalian Spermatogonial Chromosomal Aberration Test.** The spermatogonial chromosomal aberration test identifies chemicals that induce structural chromosomal aberrations in male germ cells and is predictive for the induction of heritable mutations. Usually, sexually mature Chinese hamsters or mice are used. Chromosomal aberrations in spermatogonial cells are readily observed in metaphases of the first or second mitotic cell division of spermatogenesis. Cytogenetic preparations for analysis of spermatogonial metaphases at 24 and 48 h after exposure allow the analysis of chromosomal aberrations in spermatocytes. A measure of cytotoxicity, and, thus, of exposure of the target cells, can be obtained by measuring the ratio between spermatogonial metaphases to either meiotic metaphases or interphase cells. The standard design of the test is not suitable for detection of aneuploidy. Although increased incidence of polyploidy may be seen as an indication for numerical chromosomal abnormalities, an increase in polyploidy *per se* does not indicate aneugenic potential because it can result from cell cycle perturbation.

53. **TG 485: Mouse Heritable Translocation Assay.** The mouse heritable translocation assay identifies chemicals that induce structural chromosomal changes in the first generation progeny of exposed males. The test is performed in mice, because of the ease of breeding and cytological verification. Sexually mature animals are used. The average litter-size of the strain should be greater than 8, and it should be relatively constant. The type of chromosomal change detected in this test system is reciprocal translocation. Carriers of translocation heterozygotes and XO-females show reduced fertility. This method is used to select first generation progeny for cytogenetic analysis. Translocations are cytogenetically observed as quadrivalents, which are comprised of two sets of homologous chromosomes (or bivalents) in meiotic cells at the diakinesis stage of meiosis of F₁ male progeny. To analyze for translocation heterozygosity one of two possible methods is used: 1) fertility testing of first generation progeny; or 2) cytogenetic analysis of all male first generation progeny. Monitoring of the litter size of the F₁ generation can provide an indication that dominant lethality is also occurring. The mouse heritable translocation test requires a large number of animals and is consequently rarely used. Moreover, expertise for the performance of the mouse heritable translocation test is no longer readily available.

3.2.3 Tests for Primary DNA Damage

54. **TG 486: Unscheduled DNA Synthesis (UDS) Test With Mammalian Liver Cells *in vivo*.** The unscheduled DNA synthesis (UDS) test identifies chemicals that induce DNA damage and subsequent repair (measured as unscheduled DNA synthesis *vs.* normal S-phase scheduled synthesis) in liver cells of

animals, commonly rats. However, this test does not detect the mutagenic consequences of the unrepaired genetic damage. Accordingly, the UDS test may be an appropriate test to detect DNA damage after exposure to chemicals that specifically target the liver, and that were positive in the Ames test. The test responds positively only to chemicals that induce the type of DNA damage that is repaired by nucleotide excision repair (mainly bulky adducts). The test is based on the incorporation of tritium-labelled thymidine into the DNA by repair synthesis after excision and removal of a stretch of DNA containing a region of damage, and the response is dependent on the number of DNA bases excised and replaced at the site of damage.

55. To conduct the UDS test, the test chemical is administered *in vivo* by the appropriate route, the liver cells are collected, generally by liver perfusion, and put into cultures. The incorporation of tritium-labelled thymidine into the liver cell DNA is conducted *in vitro*, and this is scored following autoradiography. The UDS test should not be considered as a surrogate for a gene mutation test and it may be less reliable than other primary DNA damage tests (Kirkland and Speit, 2008).

56. **TG 489: *In vivo* Mammalian Alkaline Comet Assay.** The comet assay identifies chemicals that induce primary DNA damage. An alternate name is the alkaline single-cell gel electrophoresis assay. Under alkaline conditions (> pH 13), the comet assay can detect single and double strand breaks in eukaryotic cells, resulting, for example, from direct interactions with DNA, alkali labile sites, as a consequence of transient DNA strand discontinuities resulting from DNA excision repair, or from processing during the assay. These DNA strand breaks may be: 1) repaired, resulting in no persistent effect; 2) lethal to the cell; or 3) fixed as a mutation resulting in a permanent heritable change. Therefore, the alkaline comet assay detects primary DNA strand breaks that do not always lead to gene mutations and/or chromosomal aberrations.

57. The comet assay can be applied to any tissue of an animal from which good quality single cell or nuclei suspensions can be prepared, including specific site of contact tissues and germ cells (Tice *et al.*, 1990). Cell division is not required. The comet assay provides an indication whether the chemical, or its metabolites, can reach DNA and cause primary strand breaks in a tissue, and, therefore, it is also useful in detecting exposure to target tissues and possible target tissues. However, neither structural chromosomal damage nor mutation is detected directly. Like many of the *in vivo* genetic toxicology tests, it can be integrated into repeat dose toxicity studies designed for other purposes (see Section 4.2.4), but because the damage it measures usually does not persist, longer exposures do not result in increased sensitivity. Accordingly, DNA damage (DNA strand breaks) should be measured shortly after exposure.

58. It should be noted that the standard alkaline comet assay as described in TG 489, is not considered appropriate to measure DNA strand breaks in mature germ cells (*i.e.* sperm). Genotoxic effects may be measured in testicular cells at earlier stages of differentiation. However, because in males the gonads contain a mixture of somatic and germ cells, positive results in the whole gonad (testis) are not necessarily reflective of germ cell damage; nevertheless, positive results indicate that the test chemical has reached the gonad and has caused genotoxicity in this tissue. Currently, testing of fresh tissue samples is recommended because freezing/thawing of sampled tissues and subsequent performance of the comet assay is not regarded as fully validated (see also paragraph 91).

59. The alkaline comet assay is most often performed in rodents, although it can be applied to other species, if scientifically justified. Further modifications of the assay allow more efficient and specific detection of DNA cross-links, or certain oxidised bases (by addition of lesion-specific endonucleases). The test guideline does not include procedures for the conduct of these modifications of the test.

60. Fragmentation of the DNA can be caused not only by chemically-induced genotoxicity, but also during the process of cell death, *i.e.* apoptosis and necrosis. It is difficult to distinguish between

genotoxicity and apoptosis/necrosis by the shape of the nucleus and comet tail after electrophoresis, *e.g.* by scoring “hedgehogs” (Guerard *et al.*, 2014; Lorenzo *et al.*, 2013). Consequently, for positive results, it is recommended that tissue samples be collected for histopathological examination to determine if apoptosis/necrosis occurred and could have resulted in DNA strand breaks via a non-genotoxic mechanism.

4 OVERVIEW OF ISSUES ADDRESSED IN THE 2014-2015 REVISION OF THE GENETIC TOXICOLOGY TEST GUIDELINES

61. As indicated in the introductory paragraphs, the Expert Workgroup undertook an extensive revision of the genetic toxicology TGs including a comprehensive harmonisation of recommendations across the TGs. This Document provides an amplification of issues considered to be important for test conduct and data interpretation and also an overview of the new recommendations.

4.1 Issues specific to *in vitro* TGs

4.1.1 Cells

62. In the recent revision to the *in vitro* TGs there is new guidance concerning the characterisation and handling/culturing of cells that are used in the individual tests. In particular, an emphasis is placed on assuring that genetic drift is avoided for cell lines. For many of the widely used mammalian cell lines, a new cell repository has been recently established and stocked with cells that are as close as possible to the original source (Lorge *et al.*, in prep).

4.1.2 Cytotoxicity and selection of highest concentration for cytotoxic chemicals

63. For the *in vitro* assays, cytotoxicity is used as a primary means for selecting test concentrations. The *in vitro* assays are conducted using measurements of cytotoxicity that have been developed and are specific to the individual assays. Since the previous revisions of the TGs, the importance of cytotoxicity, and the possibility that biologically irrelevant positive results, can be obtained at high levels of cytotoxicity has been recognised (Lorge *et al.*, 2008). The recommendations for measuring cytotoxicity and the appropriate levels of cytotoxicity are now clearly emphasised in the individual TGs and are summarised here. These changes were implemented to standardise interpretation of assay results and guide the conduct of testing to increase the reliability and acceptability of the data by providing clearer standards for measuring cytotoxicity and ensuring that the most appropriate limit concentration is used when testing cytotoxic chemicals. It should be noted that for *in vitro* assays, the treatment period is relatively short (generally 3 to 24 hours). It is not useful to conduct longer term *in vitro* exposures. This is because some of the endpoints, particularly the cytogenetic endpoints, do not accumulate with time, and most actually decrease with time (either because they are diluted by differential growth or eliminated by apoptosis). In order to detect genetic damage, *in vitro* tests are conducted up to high test chemical concentrations in order to induce detectable levels of genetic damage under short treatment periods. Therefore, information on *in vivo* exposure concentrations are not relevant to the selection of exposures used in *in vitro* assays that are set based on the physiology of the mammalian cells under the conditions of the *in vitro* assay. This characteristic is consistent with the use of *in vitro* tests for hazard identification.

4.1.2.1 *in vitro* cytogenetic assays

64. The proper conduct of the *in vitro* cytogenetic assays requires assuring that the cells in all of the test cultures have undergone cell division and have achieved a high proportion of dividing cells in the negative control/untreated cultures. The reduction of cell proliferation is usually used to evaluate cytotoxicity. Two new measures of cytotoxicity for the *in vitro* cytogenetic assays, the Relative Increase in

Cell Count (RICC) and Relative Population Doubling (RPD), have been developed and are now recommended in the revised TGs 473 and 487 for use with cell lines. Previously recommended methods such as Relative Cell Counts (RCC), trypan blue, and other vital stains, and optical evaluation of confluence or cell density are no longer recommended because they do not demonstrate that the cells are dividing. Passage through at least part of mitotic cycle is required before a micronucleus or chromosomal aberration is created. The new measures are, thus, more directly related to the end points. It should be noted that RPD is thought to underestimate cytotoxicity in cases of extended sampling time (e.g. treatment for 1.5-2 normal cell cycle lengths and harvest after an additional 1.5-2 normal cell cycle lengths, leading to sampling times longer than 3-4 normal cell cycle lengths in total) as stated in the revised TGs. Under these circumstances RICC might be a better measure for cytotoxicity. Alternatively, the evaluation of cytotoxicity after a 1.5-2 normal cell cycle lengths would be a helpful estimate. For the micronucleus assay, in addition to RICC and RPD, the Cytokinesis Blocked Proliferation Index (CBPI), or the replication index (RI) continue to be acceptable measures of cytotoxicity. For certain chemical classes, e.g. surfactants, the CBPI may underestimate cytotoxicity in *in vitro* micronucleus assays using cytoB. Mitotic index continues to be recommended for the chromosomal aberration assay when using primary cultures of lymphocytes for which, in contrast to immortalised cell lines, RPD and RICC may be impractical to measure.

65. The top level of cytotoxicity for assay acceptance has been more explicitly defined for the *in vitro* cytogenetic assays, and it should be noted that this level differs from that requested by other guidelines/guidances. It is now recommended that if the maximum concentration is based on cytotoxicity, the highest concentration should aim to achieve $55 \pm 5\%$ cytotoxicity using the recommended cytotoxicity parameters (*i.e.* reduction in RICC, RPD, CBPI, RI, or MI to $45 \pm 5\%$ of the concurrent negative control). Care should be taken in interpreting positive results found only in the higher end of this $55 \pm 5\%$ cytotoxicity range.

4.1.2.2 *in vitro* gene mutation assays

66. The *in vitro* gene mutation assays require that the cells grow through the expression phase of the assay, and also during the cloning for mutant selection. Therefore, they can only be conducted using concentrations that are compatible with cell survival and proliferation. For the MLA, TG 490 now clearly articulates that only the Relative Total Growth (RTG), originally defined by Clive and Spector (1975), should be used as the measure for cytotoxicity. RTG was developed to take into consideration the relative (to the negative control) cell growth of the treated cultures during the treatment and expression periods, and the cloning efficiency at the time of mutant selection. For the other *in vitro* gene mutations assays (TK6, *Hprt* and *xprt*) the relative survival (RS) should be used. RS is the relative cloning efficiency of cells plated immediately after treatment and corrected to include any cell loss during treatment. That is, RS should not be based solely on the plating efficiency of those cells that survive the treatment. The appropriate calculations to correct for cell loss during treatment are included in the TGs. In addition, for assays using RS as the measure of cytotoxicity, the cells used to determine the cloning efficiency immediately after treatment should be a representative sample from each of the respective untreated and treated cell cultures. For the *in vitro* gene mutation assays, if the maximum concentration is based on cytotoxicity, the highest concentration should aim to achieve between 20 and 10% RTG for the MLA, and between 20 and 10% RS for the TK6, *Hprt* and *xprt* assays. TG 490 (for the MLA and TK6 assays) indicates that, care should be taken when interpreting positive results found only between 20 and 10% RTG/RS, and a result would not be considered positive if the increase in MF occurred only at or below 10% RTG/RS. TG 476 (for the *Hprt* and *xprt* assays) indicates that care should be taken when interpreting positive results only found at 10% RS or below.

4.1.3 Selection of highest concentration tested for poorly soluble and/or non-cytotoxic chemicals

67. TG 471 was not updated in the current round of revisions. Therefore, there are no new recommendations for the Ames test and the top concentration for the Ames test is 5000 µg/plate in the absence of cytotoxicity at lower concentrations or problems with solubility

68. In this current round of revisions of the *in vitro* TGs, new recommendations are made for chemicals that are poorly soluble (unable to reach the recommended top concentration or cytotoxicity without using concentrations that are not soluble in the test culture) and/or non-cytotoxic. For poorly soluble test chemicals that are not cytotoxic at concentrations below the lowest insoluble concentration, and even if cytotoxicity occurs above the lowest insoluble concentration, it is required to test at only one concentration producing turbidity, or with a visible precipitate, because artefactual effects may result from the precipitate. Turbidity, or a precipitate visible by eye, or with the aid of an inverted microscope, should be evaluated at the end of the treatment with the test chemical. Although it is not specifically included in the TGs, care should be taken in interpreting a positive result that is only seen at the precipitating concentration.

69. Previously, the recommended top concentration, in the absence of cytotoxicity/solubility issues, was 10 mM or 5000 µg/ml (whichever is lower). The 10 mM limit was defined originally as a limit low enough to avoid artefactual increases in chromosome damage and/or mutations due to excessive osmolality and appeared high enough to ensure detection (Scott *et al.*, 1991). Based on data from a number of independent reports (Brunton *et al.*, 2002; Kirkland *et al.*, 2007, 2008; Parry *et al.*, 2010; Kirkland and Fowler, 2010; Morita *et al.*, 2012), there was unanimous agreement during the recent OECD TG revision discussions that the top concentration could be lowered. The reduction should result in an improvement of the specificity of the tests without losing sensitivity. An analysis of the data set generated by Parry *et al.* (2010) suggests that 10 mM is still required to detect biologically relevant effects from lower molecular weight non-cytotoxic chemicals, and that test sensitivity at 10 mM is more similar to 2000 than to 5000 µg/ml (Brookmire *et al.*, 2013). Based on extensive discussion, the decision was made that if toxicity and solubility are not limiting factors, the combination of 10 mM or 2000 µg/ml, whichever is lower, represents the best balance between mM and µg/ml concentrations. [Note: these limits differ from those published by the ICH (ICH, 2011)]. A document was prepared that details the analysis that was conducted and provides the rationale for this new recommendation for top concentration (in the absence of cytotoxicity or issues of solubility; see Appendix A).

70. However, when the composition of the test chemical is not defined [*e.g.* chemical of unknown or variable composition, complex reaction products, biological materials (*i.e.* UVCBs), environmental extracts, complex mixtures of incompletely known composition], the top concentration in the absence of sufficient cytotoxicity may need to be higher (*e.g.* 5 mg/ml) to increase the concentration of each of the components.

4.1.4 Treatment duration and sampling time

71. The treatment durations and sampling times for each of the *in vitro* assays is clarified in the TGs. For both the chromosomal aberration and micronucleus assays, the cells should be exposed for 3 to 6 hours without and with metabolic activation. The cells should be sampled for scoring at a time that is equivalent to about 1.5 normal cell cycle lengths after the beginning of treatment for the chromosomal aberration assay, and 1.5 to 2.0 normal cell cycle lengths after the beginning of treatment for the micronucleus assay. In addition, an experiment should be conducted in which cells should be continuously exposed without metabolic activation until they are sampled at a time equivalent to about 1.5 normal cell cycle lengths for the chromosomal aberration assay and 1.5 to 2.0 normal cell cycle lengths for the micronucleus assay. The reason for the difference in sampling times for chromosomal aberration and micronucleus analysis is that more time is needed for the cells to divide in order to see micronuclei in the daughter cells. In addition the

in vitro micronucleus TG (487) permits the application of extended sampling times if it is known, or suspected, that the test chemical affects the cell cycling time (e.g. when testing nucleoside analogues). Sampling times may be extended by up to a total 3.0 to 4.0 cell cycle lengths after the beginning of treatment, but care should be taken to ensure that the cells are still actively dividing during the extended sampling time.

72. The gene mutation assays have different recommendations depending upon the locus used. For assays using the *Hprt* or *gpt* gene, TG 476 indicates that 3 to 6 hours of exposure (both with and without metabolic activation) is usually adequate. For the *TK* gene (TG 490), 3 to 4 hours of exposure (both with and without metabolic activation) is usually adequate. There is a new recommendation for the MLA that if the short-term treatment yields negative results and there is information suggesting the need for a longer treatment (e.g. nucleoside analogs or poorly soluble chemicals) that consideration should be given to conducting the test with a longer treatment (*i.e.* 24 hours without S9). Consistent with the 1997 version of TG 476, there is, however, no requirement for the MLA that the longer treatment be routinely conducted if the short treatment is negative; note that this differs from the ICH recommendation (ICH, 2011). Following treatment, the newly induced gene mutations require time for the key enzyme levels (HPRT, XPRT or TK) to decline before they can be successfully recovered as selective agent resistant colonies. Therefore, the cells are cultured for a period of time that has been shown to provide for optimal phenotypic expression. For both *Hprt* and *xprt* mutants the recommendation is to allow a minimum of 7 to 9 days post treatment for expression. Newly induced *TK* mutants express much faster than *Hprt* or *xprt* mutants and because the small colony/slow growing mutants have doubling times much longer than the rest of the cell population, their mutant frequency actually declines once they are expressed. Therefore, it is important that the recommended expression periods of 2 days (post treatment) for the MLA and 3 to 4 days (post treatment) for TK6 are followed.

4.1.5 Concentration selection and minimum number of test concentrations/cultures

73. The revised/new *in vitro* TGs include updated recommendations on the selection and minimum number of test cultures meeting the acceptability criteria (appropriate cytotoxicity, number of cells, appropriate background frequency, *etc*) that should be evaluated. There is also additional guidance identifying situations where it may be advisable to use more than the minimum number of concentrations. The decision was made to continue to recommend at least 3 analysable test concentrations for the *in vitro* cytogenetic assays, and four for the *in vitro* gene mutations assays. For all assays, the solvent and positive control cultures are to be included in addition to the minimum number of test chemical concentrations. It is now recommended that, while the use of duplicate cultures is advisable, either replicate or single treated cultures may be used at each concentration tested provided the same total number of cells are scored in the cytogenetic assays for either single or duplicate cultures. For the cytogenetic assays (as discussed further in Section 4.3) the most important point is that the total number of cells scored at each concentration should provide for adequate statistical power. Therefore, the results obtained for replicate cultures at a given concentration should be reported separately, but they can be pooled for data analysis. Combining data from the duplicate cultures is particularly relevant for cytogenetic assays where it is important to score the recommended number of cells (either in the single or between the duplicate cultures). For test chemicals demonstrating little or no cytotoxicity, concentration intervals of approximately 2 to 3 fold will usually be appropriate. Where cytotoxicity occurs, concentrations should be selected to cover the cytotoxicity range from that producing the top level of cytotoxicity recommended for the particular assay (see Section 4.1.2) and including concentrations at which there is moderate to little or no cytotoxicity. Many test chemicals exhibit steep concentration response curves. Accordingly, in order to cover the whole range of cytotoxicity, or to study the concentration response in detail, it may be necessary to use more closely spaced concentrations and more than 3 or 4 concentrations. It may also be useful to include more than 3 or 4 concentrations, particularly when it is necessary to perform a repeat experiment.

4.1.6 Metabolic Activation

74. While some chemicals are reactive and able to directly interact with the DNA and to exert their genotoxic and/or mutagenic effects, many need to be metabolised and transformed into the reactive metabolites that interact with DNA. Unfortunately, most commonly used cell lines lack the ability to metabolise chemicals. The most commonly used activating system is the S9 fraction prepared from the homogenised livers of rats pre-treated with PCBs, or other agents, which induce the P450 mixed function oxidase (“phase I”) system. This practice arose due to the prevalence of studies available in the 1970s suggesting that oxidative metabolism of pro-mutagens to metabolites capable of electrophilic covalent modification of DNA was the major source of concern. In the absence of practical alternatives, this remains the most common approach, particularly when screening chemicals for which there are no preliminary data on which to base an alternative approach. Preparation of S9 liver homogenates from other species is possible. Previously *in vitro* screening for genetic toxicity was commonly performed using mouse or hamster S9, which substitutes for rat S9 preparations. Human liver S9 preparations are sometimes used especially in the case of follow-up studies on chemicals with species-specific metabolic differences, such as aromatic amines (Cox *et al.*, 2016). S9 fractions prepared from homogenates of other organs have been used, with kidney and lung being the most common reported in the literature (Bartsch *et al.*, 1982).

75. Metabolism, other than phase I metabolism, is required to metabolise some pro-carcinogens to the carcinogenic/mutagenic form. For example, phase II sulfonation of phase I oxidation products is known to activate some aromatic amines and alkenyl benzenes to carcinogenic metabolites. While the phase II enzymes are present in the S9 fraction, the co-factors required for phase II metabolism are generally not added because phase II metabolism is known to transform many phase I metabolites into non-mutagenic metabolites. Moreover, there are no widely accepted protocols for studying the genotoxicity of the products of other metabolic pathways. The use of metabolically competent cells has shown promise for wider application in the future (Kirkland *et al.*, 2007). The use of non-standard metabolic systems is always appropriate provided scientific justification and appropriate controls are used.

4.2 Issues specific to *in vivo* TGs

4.2.1 Dose Selection

76. Measurement of toxicity is used for two objectives: (1) to better define the doses to be used; and (2) to demonstrate sufficient exposure of the target tissues.

4.2.1.1 Range-finding study

77. Dose levels should be based on the results of a dose range-finding study measuring general toxicity that is conducted by the same route of exposure and the same duration which will be used in the main experiment, or on the results of pre-existing sub-acute toxicity studies. Any dose range-finding study should be performed with due consideration to minimising the number animals used. Chemicals with specific biological activities at low non-toxic doses (such as hormones and mitogens), and chemicals that exhibit saturation of toxicokinetic properties may be exceptions to the dose-setting criteria and should be evaluated on a case-by-case basis. The dose levels selected should cover a range from little or no toxicity up to the Maximum Tolerated Dose (MTD).

4.2.1.2 Maximum Tolerated Dose (MTD)

78. When toxicity is the limiting factor, the top dose is usually the MTD, which is defined as the highest dose that will be tolerated without evidence of study-limiting toxicity such that higher dose levels, based on the same dosing regimen, would be expected to produce lethality or evidence of pain, suffering or distress necessitating humane euthanasia (OECD, 2000). The MTD is established in range-finding studies

by measuring clinical effects and mortality, but it can also be identified from other toxicity studies in the same animal strain. In keeping with the 3Rs principles, animal use in determination of the MTD should be minimised; accordingly, a tiered range-finding study is recommended. The dose finding study should start with the lowest dose in a pre-selected core dose range (Fielder et al 1992). If the MTD is not determined with this first group of animals, a further group of animals should be exposed to a higher, or lower, dose depending on the clinical effects of the first dose. This strategy should be repeated until the appropriate MTD is found. Animals should be monitored for clinical signs of distress and excess toxicity, and identified animals should be euthanised prior to completion of the test period in this, and all other, phases of the complete study (OECD, 2000).

4.2.1.3 *Limit Dose*

79. If toxicity from dose-finding investigations, or existing data from related animal strains, indicate no observable toxicity, and if genetic toxicity is not expected based on data from *in vitro* genetic toxicology studies, or structurally related chemicals, the limit dose is 2000 mg/kg bw/day for a treatment period of less than 14 days, and 1000 mg/kg bw/day for a treatment period of 14 days or more. For certain types of test chemicals covered by specific regulations (e.g. human pharmaceuticals) these limits may vary.

80. Furthermore, for TGs 474, 475, 486, and 488 the use of a single treatment at the limit dose (rather than a full study using 3 dose levels) may be considered for chemicals meeting the above-mentioned non-toxicity criteria. The single limit dose provision was retained in these revised *in vivo* TGs in order to strike a balance between the need to prevent false negative results and reduce the number of animals used. This provision does not include TGs 478, 483, and 489 for which the full 3-dose regimen applies.

4.2.1.4 *Dosing and route of administration*

81. In general, the anticipated route of human exposure should be used; however, other routes of exposure (such as drinking water, subcutaneous, intravenous, topical, inhalation, intratracheal, dietary, or implantation) may be acceptable where they can be justified. It should be noted that intraperitoneal injection is specifically listed as not recommended in the revised TGs because it is not a physiologically relevant route of human exposure, and should only be used with specific scientific justification, e.g. to obtain historical positive control data. The maximum volume of liquid that can be administered by gavage or injection at one time depends on the size of the test animal. The volume should not normally exceed 1 mL/100g body weight (note: this limitation is not mentioned in TG 488) except in the case of aqueous solutions where a maximum of 2 mL/100g may be used. In rare cases, the use of volumes greater than this may be appropriate and should be justified. Except for irritating or corrosive chemicals, which will normally reveal exacerbated effects at higher concentrations, variability in test volume should be minimised by adjusting the concentration to ensure a constant volume at all dose levels.

4.2.2 *Proof of exposure (bioavailability)*

82. One of the more challenging issues in *in vivo* genetic toxicology testing is to judge whether the target tissues have received sufficient exposure when negative results have been obtained. Convincing evidence is required in order to conclude that sufficient exposure to a tissue (i.e. bioavailability) has been obtained to justify the conclusion that the test chemical is non-genotoxic or non-mutagenic in that test.

83. For studies investigating genotoxic effects in the blood, bone marrow, or other well-perfused tissues, indirect evidence of target tissue exposure is generally sufficient to infer tissue exposure. Examples are absorption, distribution, metabolism, and excretion (ADME or toxicokinetic) data obtained from previous or subsequent studies. However, due caution should be applied when interpreting clinical signs as indicators of systemic exposure. In addition, due consideration should be given to the possibility that short-lived metabolites may not reach the tissue being investigated, even when the chemical or metabolites are present in the circulatory system (Cluet *et al.*, 1993). In such cases, it may be necessary to determine the

presence of test chemical and/or metabolites in samples of the target tissue(s) being studied. Consequently, without the demonstration of bioavailability the value of a negative test is limited. Furthermore, if there is evidence that the test chemical(s), or its metabolite(s) will not reach the target tissue it is not appropriate to use the particular *in vivo* test. It should be noted that for short-lived reactive metabolites that initiate mutagenicity/genotoxicity, it may be almost impossible to determine whether the metabolite can enter the target tissue in reactive form or detoxified form. In this context “target tissue” refers to the tissue in which genotoxicity is being measured in a particular test guideline. Prediction of genotoxicity in specific tissues beyond those in which measurements are made is beyond the intended use of these TGs.

84. Direct evidence of target tissue exposure may be obtained from signs of toxicity in the target tissue, from toxicokinetic measurements of the chemical or its metabolites in the tissue, or evidence of DNA adducts. For the new TG 489 (comet assay), histopathological changes are considered a relevant measure of tissue toxicity. Changes in clinical chemistry measures, *e.g.* aspartate aminotransferase (AST) and alanine aminotransferase (ALT), can also provide useful information on tissue damage and additional indicators such as caspase activation, terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) stain, Annexin V stain, *etc.* may also be considered. However, there are limited published data where these indicators have been used for *in vivo* studies to measure tissue exposure.

4.2.3 Tissue selection, duration of treatment and sampling time

85. The treatment duration is dependent on the requirements and limitations of each test endpoint, as well as the relationship to the intended, or presumed, exposure of the test chemical, if there is a choice of treatment duration in the TG. Appendix B shows the durations of treatment and sampling times for the *in vivo* tests (other feasible regimens can be used if justified scientifically). In selecting exposure duration, it should be noted that gene mutations in transgenic animals could accumulate over time because the genes are “neutral”. That is, the mutant cells are at neither a selective advantage nor a disadvantage. For the other endpoints, including chromosomal aberrations, micronucleus formation (except as noted in Section 4.2.4), and DNA damage (comet), most events are either repaired or eliminated through apoptosis. Therefore, they do not accumulate over time and must be measured shortly after the last test chemical administration. For such endpoints, even when measured in experiments with chronic exposure, most events that are scored are those resulting only from the recent exposure and not the full duration of exposure.

4.2.3.1 Chromosomal aberrations and micronuclei (TG 475, TG 474, TG 483)

86. The selection of tissues for analysis of somatic chromosomal aberrations or micronuclei is fairly limited. Currently there are only test guidelines available for effects induced in the bone marrow that are subsequently detected in the bone marrow *per se*, or in peripheral blood. Methods for measurement of micronucleus induction in other tissues are being developed, but are not currently described in these TGs (*e.g.* Uno 2015a and b).

4.2.3.2 Transgenic Rodent Somatic and Germ Cell Gene Mutation Assays (TG 488)

87. Mutations in transgenic rodents can be studied in any tissue from which sufficient DNA can be extracted. The rationale for selection of tissue(s) to be analysed should be defined clearly. It should be based upon the reason for conducting the study together with any existing ADME, genetic toxicity, carcinogenicity or other toxicity data for the test chemical under investigation. Important factors for consideration include the route of administration [based on likely human exposure route(s)], the predicted tissue distribution and absorption, and the role of metabolism and the possible mechanism of action. Site of contact tissues relevant to the route of administration should be considered for analysis. If studies are conducted to follow up carcinogenicity studies, target tissues for carcinogenicity should be included. In order to reduce the need for additional animal experiments, it is recommended that a number of tissues of

potential future interest (including germ cells), in addition to those of initial interest, should be collected and frozen for later analysis.

88. Since the induction of gene mutations is dependent on cellular proliferation, a suitable compromise for the measurement of mutant frequencies in both rapidly and slowly proliferating tissues is 28 consecutive daily treatments with sampling 3 days after the final treatment (*i.e.* 28+3 protocol); although the maximum mutant frequency may not manifest itself fully in slowly proliferating tissues under these conditions. It is important to note that TG 488 states that if slowly proliferating tissues are of particular importance, then a later sampling time of 28 days following the 28 day administration period may be more appropriate when justified (Heddle *et al.*, 2003; Thybaud *et al.*, 2003). In such cases, the later sampling time would replace the 3 day sampling time.

89. TG 488 notes that the 28+3 protocol may not be optimal for detection of mutations in spermatogonial stem cells, but can provide some coverage of cells exposed across the majority of phases of germ cell development, and may be useful for detecting some germ cell mutagens. Therefore, for tests focused on somatic tissues, it is recommended that, where possible, seminiferous tubules and spermatozoa from the cauda epididymis also be collected and stored in liquid nitrogen for potential future use.

90. Accordingly, studies designed specifically to detect mutagenic effects in male germ cells require additional considerations. In such cases when spermatozoa from the cauda epididymis, and seminiferous tubules from the testes are collected, care should be taken to ensure that the treatment-sampling times are appropriate and allow the detection of effects in all germ cell phases. Currently, TG 488 specifies that (in addition to the 28+3 protocol) a 28+49 regimen (mouse) or a 28+70 regimen (rat), should be included to provide the optimal time for collecting spermatozoa from the cauda epididymis that were stem cells at the time of treatment. This requirement doubles the number of animals required. Accordingly, research is now underway to establish a suitable single, compromise sampling time, such as the 28+28 regimen described above for slowly proliferating tissues that would be suitable for both somatic and male germline tissues. It is expected that this research will support a current OECD project directed at updating TG 488 in the near future.

4.2.3.3 *in vivo* Mammalian Alkaline Comet Assay (TG 489)

91. DNA damage can be studied in most tissues using the comet assay provided that good quality cells or nuclei can be prepared. Proliferation is not required to reveal effects in the comet assay; otherwise, the discussion of tissue selection in the previous section also applies to the comet assay. However, care should be taken, and ADME parameters considered, when selecting the sampling time(s) since the DNA damage is rapidly repaired. A sampling time of 2-6 h after the last treatment for two or more treatments, or at both 2-6 and 16-26 h after a single administration are specified in TG 489. It should be noted that there is no consensus among experts about the validity of the use of tissue, or cell, suspensions that have been frozen, rather than analysed immediately after necropsy (Speit 2015). It is thus described in Annex 3 of the TG which presents the current limitations of the assay. This annex indicates that if used, the laboratory should demonstrate competency in freezing methodologies and confirm acceptable low ranges of % tail DNA in target tissues of vehicle treated animals, and that positive responses can still be detected. In the literature, the freezing of tissues has been described using different methods. However, currently there is no agreement on how to best freeze and thaw tissues, and how to assess whether a potentially altered response may affect the sensitivity of the test.

4.2.4 *Combination/integration of tests*

92. There is a worldwide interest in reducing the use of experimental animals. In the spirit of the 3Rs principles, the combination of two or more endpoints in a single genetic toxicology study is strongly

encouraged whenever possible, and when such combinations can be scientifically justified. Examples of such test combinations are: 1) the *in vivo* bone marrow micronucleus test and liver comet assay (Hamada *et al.*, 2001, Madrigal-Bujaidar *et al.*, 2008, Pfuhler *et al.*, 2009, Bowen *et al.*, 2011); 2) genetic toxicology studies and repeated dose toxicity studies (Pfuhler *et al.*, 2009; Rothfuss *et al.*, 2011); and 3) the bone marrow micronucleus test and the transgenic rodent gene mutation assay (Lemieux *et al.*, 2011).

93. Ideally, the assays being combined should have similar treatment and sampling regimens (see Appendix B). There are major considerations concerning the compatibility of test combinations with respect to these factors: 1) the effective length of the administration time; 2) the longevity of the genetic damage; and 3) the sampling time for the assays selected. For example, the micronucleus assay detects only damage that occurs in the 24 to 72 hours prior to tissue sampling if PCEs are examined, so, when combined with an assay using a 28 day sub-chronic administration time, the PCE/micronucleus assay will detect only micronuclei induced in the last 72 hours of the 28-day treatment. However, the incidence of NCEs sampled after a 28 day administration period in mouse peripheral blood provides a steady state index of average damage during the full treatment period (Witt *et al.*, 2000). Accordingly, the NCE/micronucleus assay can be more readily incorporated into other assays using a 28 day treatment period.

94. To combine the *in vivo* micronucleus assay with the TGR assay, two sampling times would be needed to meet the sampling requirements of the standalone MN and TGR assays. While this can be accomplished by drawing blood at 48 hour post-treatment for the flow cytometry MN assay and then sampling the tissues from the animals at 72 hour for the TGR assay, it still does not overcome the issue of the (arguably small) difference in the total effective dose delivered for the MN assay *vs.* the transgene mutation assay. A better alignment of doses can be accomplished when all assays in a test combination have the same effective “treatment window” and “endpoint enumeration window”, such as would be accomplished with the MN assay and the comet assay. The possibility also exists to combine non-genotoxicity assays, such as the Repeated Dose Oral Toxicity Study (TG 407), with genetic toxicology tests (preferably with the same treatment protocol), but compromises with respect to treatment and sampling times will still have to be made, since the oral toxicity test ends on day 28 and genetic toxicity tests require a sampling time after day 28. Recommendations have also been made to integrate the Dominant Lethal Test (TG 478) with the Combined Repeated Dose Toxicity Study with the Reproduction/Developmental Toxicity Screening Test (TG 422; Yauk *et al.*, 2015). In summary, while there is a residual compatibility issue with respect to sampling times of most assays, this issue could be overcome if minor changes in the sampling regimen of combined assays can be made that would not adversely affect the sensitivity of these assays.

4.2.5 Use of one or both sexes

95. While there have been studies showing isolated examples of sex differences, in general, the response of genetic toxicology tests is similar between male and female animals (Hayashi *et al.*, 1994; Ding *et al.*, 2014) and, therefore, most studies using TG 474 and TG 475 could be performed in either sex. While TG 488 can be performed using either sex, males are used if germ cell effects are a consideration. Historically, most comet assay data have been collected using only males. Accordingly, there are little, if any, data examining sex differences in comet response. Data demonstrating relevant differences between males and females (*e.g.* differences in systemic toxicity, metabolism, bioavailability, bone marrow toxicity, *etc.*) observed in a range-finding study would encourage the use of both sexes. When a genetic toxicology test is incorporated into a test in which both sexes are being exposed, an increased statistical power can be gained by analysing tissue from both sexes. Where human exposure to chemicals may be sex-specific, as for example with some pharmaceuticals, the test should be performed with the appropriate sex.

4.2.5.1 Factorial design

96. In cases where both sexes are used, it may be advantageous to use a factorial design for the study, because the analysis will identify interaction effects between sex and treatment, and, if there are no interaction effects, it will provide greater statistical power. TGs 474, 475, and 489 provide a detailed description for use and interpretation of factorial designed studies in Annex B of these TGs.

4.2.6 Age range of animals

97. The starting age range of animals (*i.e.* rodents) varies according to the TG. For the *in vivo* MN (TG 474), *in vivo* CA (TG 475), and *in vivo* comet (TG 489) assays, it is 6 to 10 weeks. For the TGR assay (TG 488) and the spermatogonial CA (SCA) assay (TG 483), it is 8 to 12 weeks to facilitate access to sufficient numbers of transgenic animals from relatively small breeding colonies (TGR), and allow time to reach sexual maturity (TGR and SCA). The Dominant Lethal Test (TG 478) specifies healthy and sexually mature male and female adult animals.

4.3 Issues common to *in vitro* and *in vivo* TGs

4.3.1 Experimental design and statistical analysis considerations

98. As a part of the TG revisions, an extensive evaluation was undertaken to analyze how the selection of specific parameters impact the overall ability of the various tests to detect induced genetic damage. In particular, this analysis better defined an appropriate approach to using spontaneous background frequencies both for individual experiment acceptability and data interpretation, and to understand the impact of assay-specific background frequencies on the statistical power of the assay. This analysis was used to develop the new recommendations for the number of cells to be treated for the *in vitro* gene mutation assays and the number of cells to be scored for the cytogenetic tests (both *in vitro* and *in vivo*). A discussion of this analysis can be found in OECD documents (OECD, 2014f).

99. Recommendations were included in the latest revisions to the TGs to discourage over-reliance on p-values associated with the statistical significance of differences found by pair wise comparisons. Statistical significance based upon a particular p-value is relevant, but is only one of the criteria used to decide whether to categorise a result as positive or negative. For example, the confidence intervals around the means for the controls and the treated cultures/animals should also be evaluated and compared within an individual experiment.

100. One of the goals for the TG revisions was to include recommendations that would insure that test results deemed to be positive would be based on biologically relevant responses. Initially it was proposed that in the revised OECD genetic toxicology guidelines, studies should be designed to detect a doubling (*i.e.* 2-fold increase) in the treated group responses over the negative control level. However, subsequent discussions focused on the fact that the sample sizes needed to detect a doubling will depend upon the background level; for example, a doubling from 1% to 2% is a smaller absolute change than one from 3% to 6%. Furthermore, it was recognised that defining the level of response required to achieve biological relevance, therefore, requires an appreciation of the nature of the endpoint, consideration of the background (negative control) incidence, and whether an absolute or relative difference versus negative control should be considered. These considerations are different for each of the assays and have been taken into account in the new recommendations found in the individual TGs.

4.3.2 Size of samples and statistical power: *in vitro* tests

101. The TGs were evaluated, and in some cases revised, to increase the power of the various assays to detect biologically significant increases. For the *in vitro* gene mutation studies, where the cell is the experimental unit, power calculations showed that designs with relatively small numbers of cells per

culture had low power to detect biologically relevant differences. For the cytogenetic tests, an acceptable level of statistical power (conventionally 80%) to detect 2 to 3 fold changes would only be achievable if the number of cells scored were increased appreciably in some tests. For revisions to the recommendations for the *in vitro* cytogenetic tests, consideration was given to both the ideal number of scored cells, and to the technical practicalities of actually scoring that number of cells, particularly for the chromosome aberration test.

102. **TG 473: *in vitro* Mammalian Chromosomal Aberration Test.** The 1997 version of TG 473 indicated that at least 200 well-spread metaphases should be scored and that these could be equally divided among the duplicates (when duplicates were used), or from single cultures. Based on a desire to increase the power of the assay, yet not make the assay too technically impractical, the number of cells to be scored was increased in this revision to at least 300 metaphases to be scored per concentration and control. As before, when replicate cultures are used the 300 cells should be equally divided among the replicates. When single cultures are used per concentration at least 300 well spread metaphases should be scored in the single culture. Scoring 300 cells has the advantage of increasing the statistical power of the test and, in addition, zero values will be rarely observed (expected to be only 5%) (OECD, 2014f). It should be noted that the number of metaphases scored can be reduced when high numbers of cells with chromosome aberrations are observed and the test chemical is considered to be clearly positive.

103. **TG 487: *in vitro* Mammalian Cell Micronucleus Test.** Based on the statistical power evaluations, a decision was made not to alter the recommendations for scoring from those made in the 2010 version of TG 487. Therefore, for the *in vitro* micronucleus test, micronucleus frequencies should be analysed in at least 2000 target cells per concentration and control, equally divided among the replicates, when replicates are used. In the case of single cultures per dose at least 2000 target cells per concentration should be scored in the single culture. If substantially fewer than 1000 target cells per culture (for duplicate cultures), or 2000 (for single culture), are available for scoring at each concentration, and if a significant increase in micronuclei is not detected, the test should be repeated using more cells, or at less cytotoxic concentrations, whichever is appropriate. When cytoB is used, a CBPI or an RI should be determined to assess cell proliferation using at least 500 cells per culture

104. **TG 476 and TG 490: *in vitro* Mammalian Cell Gene Mutation Tests.** In the 1997 version of TG 476, a general recommendation was made concerning the number of cells that should be used in all of the *in vitro* gene mutation assays. The TG indicated that the minimal number of viable cells surviving treatment, and used in each stage of the test, should be based on the spontaneous mutant frequency and that number of cells should be at least ten times the inverse of the spontaneous mutant frequency. Furthermore, at least 1 million cells were recommended. The revision to TG 476 and the new TG 490 continue to recommend that the minimum number of cells used for each test (control and treated) culture at each stage in the test should be based on the spontaneous mutant frequency. Emphasis is now, however, placed on assuring that there is a minimum number of spontaneous mutants maintained in all phases of the test (treatment, phenotypic expression and mutant selection). The expert workgroup chose to use the recommendation of Arlett *et al.*, (1989) which advocates, as a general guide, the treatment and passage of sufficient numbers of cells in each experimental culture to maintain at least 10 but ideally 100 spontaneous mutants.

105. **TG 476: *in vitro* Mammalian Cell Gene Mutation Tests using the *hprt* and *xprt* genes.** For the HPRT assay, the spontaneous mutant frequency is generally between 5 and 20 x 10⁻⁶. For a spontaneous mutant frequency of 5 x 10⁻⁶ and to maintain a sufficient number of spontaneous mutants (10 or more), even for the cultures treated at concentrations that cause 90% cytotoxicity during treatment (10% RS), it would be necessary to treat at least 20 x 10⁶ cells. In addition a sufficient number of cells (but never less than 2 million) must be cultured during the expression period and plated for mutant selection.

106. **TG 490: *in vitro* Mammalian Cell Gene Mutation Tests Using the Thymidine Kinase Gene.** For the MLA, the recommended acceptable spontaneous mutant frequency is between 35-140 x 10⁻⁶ (agar version) and 50-170 x 10⁻⁶ (microwell version). To have at least 10 and ideally 100 spontaneous mutants surviving treatment for each test culture, it is necessary to treat at least 6 x 10⁶ cells. Treating this number of cells, and maintaining sufficient cells during expression and cloning for mutant selection, provides for a sufficient number of spontaneous mutants (10 or more) during all phases of the experiment, even for the cultures treated at concentrations that result in 90% cytotoxicity (as measured by an RTG of 10%) (Lloyd and Kidd, 2012; Mei *et al.*, 2014; Schisler *et al.*, 2013).

107. For the TK6, the spontaneous mutant frequency is generally between 2 and 10 x 10⁻⁶. To have at least 10 spontaneous mutants surviving treatment for each culture it is necessary to treat at least 20 x 10⁶ cells. Treating this number of cells provides a sufficient number of spontaneous mutants (10 or more) even for the cultures treated at concentrations that cause 90% cytotoxicity during treatment (10% RS). In addition a sufficient number of cells must be cultured during the expression period and plated for mutant selection (Honma and Hayashi 2011).

4.3.3 Size of samples and statistical power: *in vivo* tests

108. Sample sizes were also increased in the *in vivo* tests to improve the power to detect increases. Statistical power increases with the number of cells scored and/or the number of animals per group (OECD, 2014f). The challenge was to select these numbers to best achieve appropriate statistical power while keeping cell numbers within practical limits, and avoiding excessive use of animals. With this goal in mind, most *in vivo* genetic toxicology TGs have been revised to achieve enhanced statistical power. For the cytogenetic tests, an acceptable level of statistical power (conventionally 80%) to detect 2 to 3 fold changes would only be achievable if the number of cells scored were increased appreciably in some tests.

109. **TG 474: Mammalian Erythrocyte Micronucleus Test.** The previous version of this TG required the scoring of 2000 or more cells per animal (5 animals per group). Statistical analyses (Kissling *et al.*, 2007; OECD, 2014f) have shown that *in vivo* designs for micronuclei with n = 5 animals have the power to detect 2 to 3-fold effects with 80% power based upon counts of about 4000 cells per animal when the background incidence is relatively high (0.1% and higher). Accordingly, the revised TG 474 now recommends at least 4000 cells per animal. The power increases with higher background control incidences. However, larger sample sizes, either as more animals and/or many more cells, would be needed to have sufficient power to detect a 2-3 fold incidence when the background incidence is lower (*i.e.* <0.1%).

110. **TG 475: Mammalian Bone Marrow Chromosome Aberration Test.** For similar statistical reasons, the minimum number of analyzed cells has been increased from 100 to 200 cells per animal with 5 animals per group from the previous version of this TG. This sample size is sufficient to detect at least 80% of chemicals that induce a 2-fold increase in aberrant cells over the historical control level of 1.0% and above at the significance level of 0.05 (Adler *et al.*, 1998b).

111. **TG 478: Rodent Dominant Lethal Test.** The original version of TG 478 contained minimal information on the conduct of this test. The revised TG 478 specifies that the number of males per group should be predetermined to be sufficient (in combination with the number of mated females at each mating interval) to provide the statistical power necessary to detect at least a doubling in dominant lethal frequency (*e.g.* about 50 fertilised females per mating; formerly 30-50). A detailed description of the recommended statistical analysis is now provided in the TG.

112. **TG 483: Mammalian Spermatogonial Chromosomal Aberration Test.** The minimum number of analysed cells in TG 483 has also been increased from 100 to 200 cells per animal with 5 animals per group (Adler *et al.*, 1994).

113. **TG 489: *In vivo* Mammalian Alkaline Comet Assay.** This new TG 489 specifies that for each sample (per tissue per animal), at least 150 cells (excluding hedgehogs) should be analysed. Scoring 150 cells per animal in at least 5 animals per dose (less in the concurrent positive control) provides adequate statistical power according to the analysis of Smith *et al.* (2008).

4.3.4 Demonstration of laboratory proficiency and establishing an historical control database

114. The revised OECD genetic toxicology TGs now include a requirement for the demonstration of laboratory proficiency. In consideration of the 3Rs, which place constraints on the use of animals, the recommendations for demonstrating laboratory proficiency are different for *in vitro* tests, for *in vivo* cell somatic tests, and for *in vivo* germ cell tests. It should be noted that the recommended methods to establish proficiency do not apply to experienced laboratories that have already been able to do so by building historical control databases of both positive and negative controls. Also, as a part of demonstrating proficiency, both initially and over time, the new TGs introduce and recommend the concept of using quality control charts to assess the historical control databases and to show that the methodology is “under control” in the individual laboratories (see Section 4.3.5.3 for more information on control charts).

115. In order to establish sufficient experience with the test prior to using it for routine testing, the laboratory should have performed a series of experiments using reference substances with different mechanisms of action. Such experiments should indicate that the laboratory can discriminate between negative and positive chemicals, and detect positive chemicals acting via different mechanisms, and requiring or not requiring metabolic activation. TGs provide recommendations for the substances that could be used for each test.

116. For *in vitro* tests and most *in vivo* somatic cell assays, a selection of positive (at least two *in vivo*) and negative control substances should be investigated under all experimental conditions of the specific test (e.g. short- and long-term treatments for *in vitro* assays, as applicable) and give responses consistent with the published literature. The literature suggests that a minimum of 10 experiments may be necessary but would preferably consist of at least 20 experiments conducted under comparable experimental conditions (Hayashi *et al.*, 2011). It is noted that this recommendation appears in most of the Test Guidelines but is absent from two *in vivo* Test Guidelines (488 and 489).

117. For *in vivo* somatic cell TGs wherein multiple tissues can be used (e.g. the *in vivo* alkaline comet assay and the transgenic rodent gene mutation assay) proficiency should be demonstrated in each tissue that is being investigated. During the course of these investigations the laboratory should establish an historical database of positive and negative control values, as described in Section 4.3.5.3.

118. For the TGR and SCA assays, and the DLT, there is currently no explicit requirement to establish an historical control database. However, competency should be demonstrated by the ability to reproduce expected negative and positive control results from published data when conducting any new study. The positive and negative control literature on the TGR assay has been compiled and is readily available in an OECD Detailed Review Paper (OECD, 2009); however, since such compiled sources are not available for the DLT and SCA assays, summaries of negative control data for these assays are presented herein (Appendices C and D respectively).

119. The negative control values for percent resorptions in the DLT varies widely, depending on the parental strains used, from 3.3 [(SECxC57BL) F1 x (C3Hx101) F1] to 14.3 [T-Stock x (CH3x101) F1]. Thus, a recommended range for the negative control value cannot be easily identified. Furthermore, some of the strains shown in Appendix C may not be generally available; therefore, laboratories should choose an available strain with stable negative control variability when planning to perform the DLT.

120. The negative control values for the percent cells with chromosomal aberrations in the SCA assay also varies among studies (Appendix D). Based on the data in this Table, TG 483 states that the recommended range for negative controls is >0 to ≤ 1.5 % of cells with chromosomal aberrations.

4.3.5 Concurrent negative and positive controls

121. In addition to establishing laboratory competence, negative and positive historical control data are important for assessing the acceptability of individual experiments, and the interpretation of test data. In particular, it is necessary to determine whether specific responses fall within or outside the distribution of the negative control. With the 3Rs principles in mind, the recommendations for positive controls differ for *in vitro* and among various *in vivo* tests.

4.3.5.1 Concurrent negative controls

122. Negative control groups are important for providing a contemporaneous control group for use in comparisons with the treated groups. This group can also be used to assess whether the experiment is of acceptable quality by comparison with a set of historical control groups.

123. Negative controls usually consist of cells or animals treated with the solvent or vehicle (*i.e.* without test chemical). They should be incorporated into each *in vitro* and *in vivo* test and handled in the same way as the treatment groups. It should be noted that when choosing a solvent or vehicle the decision should be based on obtaining maximum solubility of the test chemical without interacting with it or test system.

124. In order to reduce unnecessary animal usage for *in vivo* tests, if consistent inter-animal variability and frequencies of cells with genotoxicity are demonstrated by historical negative control data at each sampling time for the testing laboratory, only a single sampling time for the negative control may be necessary. Where only a single sampling time is used for negative controls, it should be the first sampling time used in the study.

4.3.5.2 Concurrent positive controls

125. The inclusion of concurrent positive controls (reference controls/well-known genotoxic chemicals) is designed to demonstrate the effectiveness of a particular genetic toxicology test on the day it is performed. Each positive control should be used at a concentration or dose expected to reliably and reproducibly result in a detectable increase over background in order to demonstrate the ability of the test system to efficiently detect DNA damage, gene mutations and/or chromosomal aberrations depending on the test, and in the case of *in vitro* tests, the effectiveness of the exogenous metabolic activation system. Therefore, positive control responses (of both direct-acting chemicals and chemicals requiring metabolic activation) should be observed at concentrations or doses that produce weak or moderate effects that will be detected when the test system is optimised, but not so dramatic that positive responses will be seen in sub-optimal test systems, and immediately reveal the identity of the coded samples to the scorer (*i.e.* for tests using coded samples).

4.3.5.2.1 In vitro tests

126. For each of the *in vitro* genetic toxicology tests, positive control substances should be assayed concurrently with the test chemical. Because *in vitro* mammalian cell tests for genetic toxicity are sufficiently standardised, the use of positive controls may be confined to a chemical requiring metabolic activation. Provided it is done concurrently with the non-activated test using the same treatment duration, this single positive control response will demonstrate both the activity of the metabolic activation system and the responsiveness of the test system. Long-term treatment should, however, have its own positive control, as the treatment duration will differ from the test using metabolic activation. In the case of the *in*

vitro micronucleus test, positive controls demonstrating clastogenic and aneugenic activity should be included. For the gene mutation tests using the *TK* locus, positive controls should be selected which induce both large and small colony (*i.e.* normal and slow-growing) mutants.

4.3.5.2.2 In vivo tests

127. For *in vivo* tests, a group of animals treated with a positive control substance should normally be included with each test. In order to reduce unnecessary animal usage when performing a transgenic rodent gene mutation, micronucleus, bone marrow chromosomal aberration, or spermatogonial chromosomal aberration test, this requirement may be waived when the testing laboratory has demonstrated proficiency in the conduct of the test according to the criteria described in the TG for each test. In such cases where a concurrent positive control group is not included, scoring of “reference controls” (fixed and unstained slides, cell suspension samples, or DNA samples from the same species and tissues of interest, and properly stored) must be included in each experiment. These samples can be collected from tests during proficiency testing or from a separate positive control experiment conducted periodically (*e.g.* every 6-18 months), and stored for future use. For the dominant lethal test, concurrent positive controls are required until laboratories have demonstrated proficiency, and then they are not required. Because of insufficient experience with the longevity of alkali labile DNA sites in storage with the comet assay, concurrent positive controls are always necessary.

128. Since the purpose of a positive control is primarily to demonstrate that the assay is functioning correctly (and not to validate the route of exposure to the tested chemical), it is acceptable that the positive control be administered by a route different from the test chemical, using a different treatment schedule, and for sampling to occur only at a single time point provided, of course, that an appropriate positive response is measured in all tissues being sampled. It is, however, important that the same route be used when measuring site-of-contact effects.

4.3.5.3 Historical control distribution and control charts

129. Historical control data (both negative and positive) should be collected for each test. The individual Test Guidelines provide recommendations for the specific parameters that should be used for compilations (*e.g.* for each species, strain, tissue, cell type, metabolic condition). All control data of each individual genetic toxicology test, strain *etc.* during a certain time period (*e.g.* 5 years), or from the last tests performed (*e.g.* the last 10 or 20 tests) should be accumulated to create the historical control data set. The laboratory should not only establish the historical negative (untreated, solvent/vehicle) and positive control ranges, but also define the distribution (*e.g.* Poisson distribution 95% control limits) as this information will be used for data interpretation. This set should be updated regularly. Any changes to the experimental protocol should be considered in terms of their impact on the resulting data remaining consistent with the laboratory’s existing historical control database. Only major changes in experimental conditions should result in the establishment of a new historical control database where expert judgment determines that it differs from the previous distribution. Further recommendations on how to build and use the historical data (*i.e.* criteria for inclusion and exclusion of data in historical data and the acceptability criteria for a given experiment) can be found in the literature (Hayashi *et al.*, 2011).

130. According to the majority of the new and revised TGs, laboratories should use quality control methods, such as control charts. Control charts are plots of data collected over a period of time with horizontal lines established to define the upper and lower bounds of the range of acceptable values for the particular assay. Control charts are long-established and widely-used methods for quality control laboratories to monitor the variability of samples and to show that their methodology is 'under control' rather than drifting over time. They also provide a visual presentation of the variability within a laboratory, which can help put any possible treatment-related effects into context. There are many different types of control charts. Examples are I-charts for plotting individual values, C-charts for plotting count data and

Xbar-charts for plotting the means of groups of individuals such as the individual units in a negative control group (OECD, 2014f).

131. Most major statistical software packages (*e.g.* SAS, SPSS, Stata, Genstat, Minitab, JMP) have procedures for producing control charts and provide guides for using the procedures. Software specifically designed for quality control methodology in general is available. The software language R has a package (*qcc*) that can produce control charts. In addition there are a number of textbooks describing the methods (Ryan, 2000, Ryan, 2011, Henderson, 2011, Montgomery, 2005 & Mullins, 2003). The US National Institute of Standards and Technology (NIST) has a detailed online description and discussion of the methodology (<http://www.itl.nist.gov/div898/handbook/pmc/pmc.htm>). There are also numerous online discussion groups in areas related to Total Quality Management (TQM), Six-sigma methodology and Statistical Process Control (SPC) that actively discuss issues in the Quality Assurance/Control field.

4.3.6 Data interpretation and criteria for a positive/negative result

132. In revising the TGs, the expert workgroup gave extensive consideration to providing more guidance than was given in the previous TGs for interpreting test data. As a result, several new concepts are included in the revised/new TGs. Prior to considering whether a particular experiment is positive or negative, it is important to ascertain whether that experiment is properly conducted. Therefore, the revised TGs clarify the acceptance criteria for each assay. In addition, guidance was developed to provide recommendations as to what defines a biologically relevant positive result. Previous TGs indicated that positive responses should be biologically relevant, but did not provide a means to determine biological relevance. The revised/new TGs include 3 equal considerations when assessing whether a response is positive or negative. First the test chemical response should be assessed as to whether there is a statistically significant increase from the concurrent negative controls. Second, the response should be concentration/dose related. Finally, a new concept, that utilises the historical negative control distributions, is introduced to provide for assessing biological relevance. For the MLA, (TG 490) the use of the GEF to define the biological relevance of the response is introduced (see below). It should be noted; however, that TGs not revised in the current round of revisions (TG 471, TG 485 and TG 486) are not impacted by this new approach.

4.3.6.1 Individual test acceptability criteria

133. The revised TGs clarify recommendations for individual assay acceptability as follows:

- the concurrent negative control is considered acceptable for addition to the laboratory historical negative control database, and/or is consistent with published norms (depending on the assay);
- concurrent positive controls induce responses that are compatible with those generated in the laboratory's historical positive control data base, and produce a statistically significant increase compared with the concurrent negative control;
- for *in vitro* assays, all experimental conditions (based on the recommended treatment times and including the absence and presence of metabolic activation) were tested unless one resulted in clear positive results;
- adequate numbers of animals/cells were treated and carried through the experiment or scored (as appropriate for the individual test);
- an adequate number of doses/concentrations covering the appropriate dose/concentration range is analyzable;

- the criteria for the selection of top dose/concentration are consistent with those described in the individual TGs.

134. Apart from the above criteria, MLA-specific acceptability criteria have been defined based on the IWGT MLA expert workgroup's data evaluation for several negative control data parameters (Moore *et al.*, 2000; 2002; 2003; 2006). Consistent with the general approach to establishing acceptability criteria for the revised genetic toxicology TGs, these recommendations are based on distributions of a very large number of experiments from laboratories proficient in the conduct of the MLA. There are also MLA-specific criteria for positive controls that assure good recovery of both small and large colony mutants. The specific recommendations (*i.e.* acceptable ranges for the main parameters) for the MLA are detailed in TG 490.

4.3.6.2 Criteria for a positive/negative result

135. If a genetic toxicity test is performed according to the specific TG, and all acceptability criteria are fulfilled (as outlined above), the data can be evaluated as to whether the response is positive or negative. The new TGs recognise it is important that chemicals determined to be positive demonstrate biologically relevant increases which are concentration/dose related. As with the acceptability criteria, the assessment of biological relevance takes the distribution of the negative control data into consideration (*e.g.* Poisson 95% control limits).

136. For both *in vitro* and *in vivo* assays (with the exception of the MLA—see below) a response is considered a clear positive in a specific test if it meets all the criteria below in at least one experimental condition:

- at least one of the data points exhibits a statistically significant increase compared to the concurrent negative control;
- the increase is concentration- or dose-related at least at one sampling time when evaluated with an appropriate trend test;
- the result is outside the distribution of the historical negative control data (*e.g.* Poisson-based 95% control limits).

137. A test chemical is considered clearly negative if, in all experimental conditions examined, none of the above criteria for a positive result are met.

138. Recommendations for the most appropriate statistical methods can be found in the literature (Lovell *et al.*, 1989; Kim *et al.*, 2000).

139. For the MLA, the IWGT MLA expert workgroup recommendation for determination of a biologically relevant positive result relies on the use of a predefined induced mutant frequency (*i.e.* increase in MF above concurrent control), designated the Global Evaluation Factor (GEF) which is based on the analysis of the distribution of the negative control MF data from participating laboratories (Moore *et al.*, 2006). For the agar version of the MLA the GEF is 90×10^{-6} , and for the microwell version of the MLA the GEF is 126×10^{-6} . Responses determined to be clear positives should also demonstrate a concentration response (which can be assessed using a trend test).

140. As outlined above, the revised/new TGs provide criteria for results that are clearly positive or negative. If the response is neither clearly negative nor clearly positive the TGs recommend that expert judgment be applied. Test results that do not meet all the criteria may also be judged to be positive or negative without further experimental data, but they need to be evaluated more closely before any final conclusion is reached. If, after the application of expert judgment, the results remain inconclusive (perhaps

as a consequence of some limitation of the test or procedure) they should be clarified by further testing, preferably using modifications of experimental conditions (*e.g.* other metabolic activation conditions, length of treatment, sampling time, concentration spacing *etc.*). In some cases re-examination of the test results (*e.g.* counting more cells from archived slides or frozen samples) may resolve the ambiguity.

141. In rare cases, even after further investigations, the data set will preclude a definitive positive or negative call. Therefore the test chemical response should be concluded to be equivocal (interpreted as equally likely to be positive or negative).

142. For all of the tests covered in the genetic toxicology TGs, there is no requirement for verification of a clear positive or negative response.

4.3.7 Chemicals that require specific approaches

143. There are some chemicals, such as nanomaterials, complex mixtures, volatiles, aerosols and gases, which require special modifications of the TGs in order to: 1) properly characterise the test chemical; 2) appropriately metabolise the chemical (see paragraphs 74-75), 3) adequately expose the cells/animals; 4) conduct an adequate test; and 5) properly interpret the test data. Guidance for these special chemicals is not described in the TGs.

4.3.8 Test batteries, weight of the evidence and interpretation of data

144. The OECD TGs provide recommendations on how to conduct the various genetic toxicology tests. However, in some cases, regulatory organisations have recommended modifications to specific guidelines appropriate for specific product types, [*e.g.* ICH (ICH, 2011)].

145. The OECD TGs do not make any specific recommendations as to which tests to use in a test battery. Regulatory agencies publish their own recommendations, which should be consulted prior to initiating testing. Generally, the recommended genetic toxicology test batteries include tests to detect gene mutations and structural as well as numerical chromosomal damage (aneuploidy) in both *in vitro* and *in vivo* tests; however, more recently, in some jurisdictions the emphasis has been on using only *in vitro*, and no, or fewer, well-chosen, *in vivo* tests.

146. There are publications that provide basic information on using genetic toxicology information for regulatory decisions (Dearfield and Moore, 2005; Cimino, 2006). In addition there have been expert workgroup discussions concerning appropriate follow-up testing strategies from chemicals found to be positive *in vitro* tests and/or *in vivo* tests (Dearfield *et al.*, 2011; Thybaud *et al.*, 2007; Thybaud *et al.*, 2011; Tweats *et al.*, 2007a, b).

147. It is important to emphasise that the results from the different assays should be evaluated in line with the applicable regulatory test strategy. The amount of data available for a weight of evidence evaluation will vary enormously, particularly among different product categories. Data-rich packages prepared for drug or pesticide regulations may permit analyses that would be impossible for chemicals involving other uses for which less data are available.

REFERENCES

- Adler, I. (1974), "Comparative cytogenetic study after treatment of mouse spermatogonia with Mitomycin C", *Mutation Research*, Vol. 23/3, pp. 369-379.
- Adler, I. (1982), "Male germ cell cytogenetics", in *Cytogenetic Assays of Environmental Mutagens*, Editor: TC Hsu, Allanheld Osmun Publishers, Totowa, New Jersey, pp. 249-276.
- Adler, I. *et al.* (1994), "International workshop on standardisation of genotoxicity test procedures", Summary report of the working group on mammalian germ cell tests. *Mutation Research*, Vol. 312, pp. 313-318.
- Adler, I. *et al.* (1995), "Clastogenicity of diepoxybutane in bone marrow cells and male germ cells of mice", *Mutagenesis*, Vol. 10/6, pp. 535-541.
- Adler, I. and A. El-Tarras (1989), Clastogenic effects of cis-diamminedichloro platinum. I. Induction of chromosomal aberrations in somatic and germinal cells of mice. *Mutation Research*, Vol. 211/1, pp. 131-137.
- Adler, I. *et al.* (1998a), "Dose response study for 1,3-butadiene-induced dominant lethal mutations and heritable translocations in germ cells of male mice", *Mutation Research*, Vol. 397/1, pp. 85-92.
- Adler, I. *et al.* (1998b), "Recommendations for statistical designs of *in vivo* mutagenicity tests with regard to subsequent statistical analysis", *Mutation Research*, Vol. 417/1, pp. 19-30.
- Adler, I. *et al.* (2002), "Induction of chromosomal aberrations by dacarbazine in somatic and germinal cells of mice", *Mutagenesis*, Vol. 17/5, pp. 383-389.
- Amundson, S. and H Liber. (1992), "A comparison of induced mutation at homologous alleles of the tk locus in human cells. II. Molecular analysis of mutants", *Mutation Research*, Vol. 267/1, pp. 89-95.
- Anderson, D. *et al.* (1998), "A comparison of male-mediated effects in rats and mice exposed to 1,3-butadiene", *Mutation Research*, Vol. 397/1, pp.77-84.
- Anderson, D. *et al.* (1976a), "Dominant lethal studies with paraquat and diquat in male cd-1 mice", *Mutation Research*, Vol. 40/4, pp. 349-358.
- Anderson, D. *et al.* (1976b), "Vinyl chloride: dominant lethal studies in male cd-1 mice", *Mutation Research*, Vol. 40/1, pp. 359-370.
- Anderson, D. *et al.* (1977), "Dominant lethal studies with the halogenated olefins vinyl chloride and vinylidene dichloride in male CD-1 mice", *Environmental Health Perspectives*, Vol. 21, pp. 71-78.
- Arlett, C. F. *et al.* (1989), "Mammalian cell gene mutation assays based upon colony formation". In: *Statistical Evaluation of Mutagenicity Test Data*, Kirkland, D.J. (Ed.), Cambridge University Press. Pp.66-101.
- Attia, S. (2012), "Dominant lethal mutations of topoisomerase II inhibitors etoposide and merbarone in male mice: A mechanistic study", *Archives of Toxicology*, Vol. 86/5, pp. 725-731.
- Attia, S. *et al.* (2015), "Dominant lethal effects of nocodazole in germ cells of male mice", *Food and Chemical Toxicology*, Vol. 77, pp. 101-104.

Avlasevich, S. L. *et al.* (2006) “In vitro micronucleus scoring by flow cytometry: differential staining of micronuclei versus apoptotic and necrotic chromatin enhances assay reliability”. *Environ. Mol. Mutagen.*, 47, 56–66.

Barnett, L. and S Lewis. (2003), “Chlornaphazine and chlorambucil induce dominant lethal mutations in male mice”, *Mutation Research*, Vol. 543/2, pp. 145-154.

Barnett, L. *et al.* (1992), “Ethylene dibromide: negative results with the mouse dominant lethal assay and the electrophoretic specific-locus test”, *Mutation Research*, Vol. 282/2, pp. 127-133.

Bartsch, H. *et al.* (1982), Chapter 3: “Metabolic activation systems *in vitro* for carcinogen/mutagen screening tests”, in *Chemical Mutagens (Vol.7): Principles and Methods for Their Detection*, de Serres, F. and A. Hollaender (eds.), Plenum Press, New York, pp. 95-162 (NY: Plenum Press

Bateman, A. (1984), “The dominant lethal assay in the male mouse”, in *Handbook of Mutagenicity Test Procedures*, 2nd Edition, Kilbey BJ, Legator M, Nichols W, Ramel C (eds.), Elsevier Scientific, Amsterdam, pp. 471-484.

Bishop, J. *et al.* (1983), “Dominant lethal test response with IMS and TEM using different combinations of male and female stocks of mice”, *Mutation Research*, Vol. 121/3-4, pp. 273-280.

Blaszowska, J. (2010), “Induction of dominant lethal mutations by *Ascaris* trypsin inhibitor in male mice”, *Reproductive Toxicology*, Vol. 29/1, pp. 113-119.

Bowen, D. *et al.* (2011), “Evaluation of a multi-endpoint assay in rats, combining the bone-marrow micronucleus test, the comet assay and the flow-cytometric peripheral blood micronucleus test”, *Mutation Research*, Vol. 722/1, pp. 7-19.

Brookmire, L. *et al.* (2013), “Evaluation of the highest concentrations used in the chromosome aberrations assay”, *Environmental and Molecular Mutagenesis*, Vol. 54/1, pp. 36-43.

Brunton, L. *et al.* (2002), “Goodman and Gilman’s *The Pharmacological Basis of Therapeutics*”, 10th Edition, McGraw-Hill, New York.

Cao, X. *et al.* (2014), “Quantitative dose-response analysis of ethyl methanesulfonate genotoxicity in adult gpt-delta transgenic mice”, *Environmental and Molecular Mutagenesis*, Vol. 55/5, pp. 385-399.

Cimino, M. (2006a), “Comparative overview of current international strategies and guidelines for genetic toxicology testing for regulatory purposes”, *Environmental and Molecular Mutagenesis*, Vol. 47/5, pp. 362-390.

Cimino, M. (2006b), *Erratum to* “Comparative overview of current international strategies and guidelines for genetic toxicology testing for regulatory purposes”, *Environmental and Molecular Mutagenesis*, Vol. 47/9, pp. 746.

Ciranni, R. and I Adler. (1991), “Clastogenic effects of hydroquinone: induction of chromosomal aberrations in mouse germ cells”, *Mutation Research*, Vol. 263/4, pp. 223-229.

Ciranni, R. *et al.* (1991), “Dose-related clastogenic effects induced by benzene in bone marrow cells and in differentiating spermatogonia of Swiss CD1 mice”, *Mutagenesis*, Vol. 6/5, pp. 417-421.

Claxton, L. *et al.* (2001), “Methods for the Spiral *Salmonella* mutagenicity assay 32 including specialised applications”, Mutation Research, Vol. 488/3, pp. 241-257.

Cliet, I. *et al.* (1993), “Lack of predictivity of bone marrow micronucleus test versus testis micronucleus test: Comparison with four carcinogens”, Mutation Research, Vol. 292/2, pp. 105-111.

Clive, D. and J Spector. (1975), “Laboratory procedure for assessing specific locus mutations at the TK locus in cultured L5178Y mouse lymphoma cells”, Mutation Research, Vol. 31/1, pp. 17-29.

COM (2011), “Guidance on a strategy for testing of chemicals for mutagenicity”, in Committee on Mutagenicity of Chemicals in Food, Consumer Products and the Environment (COM), Department of Health, London.

Corvi, R. *et al.* (2008), “ECVAM retrospective validation of the *in vitro* micronucleus test (MNT)”, Mutagenesis, Vol. 23/4, pp. 271-283.

Cox, J. *et al.* (2016), “The utility of metabolic activation mixtures containing human hepatic post-mitochondrial supernatant (S9) for *in vitro* genetic toxicity assessment”, Mutagenesis, Vol. 31/2, pp.117-130..

Dearfield, K. and M Moore. (2005), “Use of genetic toxicology information for risk assessment”, Environmental and Molecular Mutagenesis, Vol. 46/4, pp. 236–245.

Dearfield, K. *et al.* (2011), “Follow-up actions from positive results of *in vitro* genetic toxicity testing”, Environmental and Molecular Mutagenesis, Vol. 52/3, pp. 177-204.

De Boeck, M. *et al.* (2005), “Flow cytometric analysis of micronucleated reticulocytes: Time- and dose-dependent response of known mutagens in mice, using multiple blood sampling”, Environmental and Molecular Mutagenesis, Vol. 46/1, pp. 30-42.

De Flora, S. and A Izzotti. (2007), “Mutagenesis and cardiovascular diseases: molecular mechanisms, risk factors, and protective factors”, Mutation Research, Vol. 621/1-2, pp. 5–17.

Dertinger, S. *et al.* (2011), “Flow cytometric scoring of micronucleated erythrocytes: An efficient platform for assessing *in vivo* cytogenetic damage”, Mutagenesis, Vol. 26/1, pp. 139-145.

Ding, W. *et al.* (2014), “Sex-specific dose-response analysis of genotoxicity in cyproterone acetate-treated F344 rats”, Mutation Research, Vol. 774, pp. 1-7.

Doherty, A. *et al.* (2011), “A rapid, semi-automated method for scoring micronuclei in mononucleated mouse lymphoma cells”, Mutation Research, Vol. 726/1, pp. 36-41.

Dunnick, J. *et al.* (1984), “Dimethyl methyl phosphonate induction of dominant lethal mutations in male mice”, Mutation Research, Vol. 138/2-3, pp. 213-218.

Eastmond, D. *et al.* (2009), “Mutagenicity testing for chemical risk assessment: update of the WHO/IPCS harmonized scheme”, Mutagenesis, Vol. 24/4, pp. 341–349.

ECHA (2008a), “Guidance on information requirements and chemical safety assessment, Chapter R.4: Evaluation of available information”. European Chemicals Agency (ECHA), Helsinki.

ECHA (2008b), "Guidance on information requirements and chemical safety assessment, Chapter R.7a: Endpoint Specific Guidance", European Chemicals Agency, Helsinki.

EC (2009), "Regulation (EC) No 1223/2009 of The European Parliament and of the Council of 30 November 2009 on cosmetic products", Official Journal of the European Union, L 342/59-209.

EC (2006), "Regulation (EC) No 1907/2006 of the European Parliament and the Council of 18 December 2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), establishing a European Chemicals Agency, amending Directive 1999/45/EC and repealing Council Regulation (EEC) No 793/93 and Commission Regulation (EC) No 1488/94 as well as Council Directive 76/769/EEC and Commission Directives 91/155/EEC, 93/105/EC and 2000/21/EC", Official Journal of the European Union, L396/1-849.

Ehling, U. (1971), "Comparison of radiation- and chemically-induced dominant lethal mutations in male mice", *Mutation Research*, Vol. 11/1, pp. 35-44.

Ehling, U. and A Neuhäuser-Klaus. (1988), "Induction of specific-locus and dominant-lethal mutations by cyclophosphamide and combined cyclophosphamide-radiation treatment", *Mutation Research*, Vol. 199/1, pp. 21-30.

Ehling, U. and A Neuhäuser-Klaus. (1989), "Induction of specific-locus and dominant lethal mutations in male mice by chlormethine", *Mutation Research*, Vol. 227/2, pp. 81-89.

Ehling, U. and A Neuhäuser-Klaus. (1991), "Induction of specific-locus and dominant lethal mutations in male mice by buslfan", *Mutation Research*, Vol. 249/2, pp. 285-292.

Ehling, U. and A Neuhäuser-Klaus. (1995), "Induction of specific-locus and dominant lethal mutations in male mice by n-propyl and isopropyl methanesulfonate", *Mutation Research*, Vol. 328/1, pp. 73-82.

Ehling, U. *et al.* (1968), "Induction of dominant lethal mutations by alkylating agents in male mice", *Mutation Research*, Vol. 5/3, pp. 417-428.

Erickson, R. (2010), "Somatic gene mutation and human disease other than cancer: An update". *Mutation Research*, Vol. 705, pp. 96-106.

Fielder, R. *et al.* (1992), "Dose setting in *in vivo* mutagenicity assays", *Mutagenesis*, Vol. 7, pp. 313-319.

Fluckiger-Isler, S. *et al.* (2004), "Assessment of the performance of the Ames II^{□□} assay: A collaborative study with 19 coded compounds", *Mutation Research*, Vol. 558/1-2, pp. 181-197.

Frank, S. (2010), "Evolution in health and medicine Sackler colloquium: Somatic evolutionary genomics: mutations during development cause highly variable genetic mosaicism with risk of cancer and neurodegeneration", *Proceedings of the National Academy of Sciences of the United States of America*, Vol. 107/Suppl 1, pp. 1725-1730.

Generoso, W. *et al.* (1975), "6-mercaptopurine, an inducer of cytogenetic and dominant-lethal effects in premeiotic and early meiotic germ cells of male mice", *Mutation Research*, Vol. 28/3, pp. 437-447.

Generoso, W. *et al.* (1982), "Lack of association between induction of dominant-lethal mutations and induction of heritable translocations with benzo[a]pyrene in postmeiotic germ cells of male mice", *Mutation Research*, Vol. 94, pp. 155-163.

Generoso, W. *et al.* (1986), "Ethylene oxide dose and dose-rate effects in the mouse dominant-lethal test", *Environmental Mutagenesis*, Vol. 8/1, pp. 1-7.

Generoso, W. *et al.* (1995), "Dominant lethal and heritable translocation tests with chlorambucil and melphalan in male mice", *Mutation Research*, Vol. 345/3-4, pp. 167-180.

Generoso, W. *et al.* (1996), "Dominant lethal mutations, heritable translocations, and unscheduled DNA synthesis induced in male mouse germ cells by glycidamide, a metabolite of acrylamide", *Mutation Research*, Vol. 371/3-4, pp. 175-183.

Generoso, W. and W Piegorsch. (1993), Chapter 8: "Dominant lethal tests in male and female mice" in *Methods in Toxicology* (Vol. 3): Part A, Male Reproductive Toxicology, Academic Press, Inc., San Diego, pp. 124-141.

Gollapudi, B. *et al.* (2013), "Quantitative approaches for assessing dose-response relationships in genetic toxicology studies", *Environmental and Molecular Mutagenesis*, Vol. 54/1, pp. 8-18.

Green, S. *et al.* (1985), "Current status of bioassays in genetic toxicology--the dominant lethal assay. A report of the U.S. Environmental Protection Agency Gene-Tox Program", *Mutation Research*, Vol. 154/1, pp. 49-67.

Guerard, M. *et al.* (2014), "Influence of experimental conditions on data variability in the liver comet assay", *Environmental and Molecular Mutagenesis*, Vol. 55/2, pp. 114-121.

Guo, C. *et al.* (2005), "The influence of aluminum exposure on male reproduction and offspring in mice", *Environmental Toxicology and Pharmacology*, Vol. 20/1, pp. 135-141.

Hamada, S. *et al.* (2001), "Evaluation of the rodent micronucleus assay by a 28-day treatment protocol: Summary of the 13th collaborative study by the collaborative study group for the Micronucleus Test (CSGMT)/Environmental Mutagen Society of Japan (JEMS)-Mammalian Mutagenicity Study Group (MMS)", *Environmental and Molecular Mutagenesis*, Vol. 37/2, pp. 93-110.

Hayashi, M., J.T. MacGregor, D.G. Gatehouse, D.H. Blakey, S.D. Dertinger, L. Abramsson-Zetterberg, G. Krishna, T. Morita, A. Russo, N. Asano, H. Suzuki, W. Ohyama, and D. Gibson (2007), *In vivo* erythrocyte micronucleus assay III. Validation and regulatory acceptance of automated scoring and the use of rat peripheral blood reticulocytes, with discussion of non-hematopoietic target cells and a single dose-level limit test, *Mutat. Res.*, 627, 10-30.

Hayashi, M. *et al.* (2011), "Compilation and use of genetic toxicity historical control data", *Mutation Research*, Vol. 723/2, pp. 87-90.

Hayashi M. *et al.* (1994), "In vivo rodent erythrocyte micronucleus assay", *Mutation Research*, Vol. 312/2, pp. 293-304.

Heddle, J. *et al.* (2003), "Treatment and sampling protocols for transgenic mutation assays", *Environmental and Molecular Mutagenesis*, Vol. 41/1, pp. 1-6.

Henderson, G. (2011), "Six Sigma Quality Improvement with Minitab", 2nd edition, John Wiley & Sons Inc., Chichester, United Kingdom.

Hoeijmakers, J. (2009). "DNA damage, aging, and cancer", *New England Journal of Medicine*, Vol. 361/15, pp. 1475-1485.

Honma, M. *et al.* (1997) "Cytotoxic and mutagenic responses to X-rays and chemical mutagens in normal and P53-mutated human lymphoblastoid cells", *Mutation Research*, Vol. 374/1, pp. 89-98.

Honma, M and Hayashi (2011), "Comparison of *in vitro* micronucleus and gene mutation assay results for P53-competent versus P53-deficient human lymphoblastoid cells", *Environmental and Molecular Mutagenesis*, Vol 52/5, pp.373-384.

Hu, Q. and S Zhu. (1990), "Induction of chromosomal aberrations in male mouse germ cells by uranyl fluoride containing enriched uranium", *Mutation Research*, Vol. 244/3, pp. 209-214.

ICH (2011), "Guidance On Genotoxicity Testing And Data Interpretation For Pharmaceuticals Intended For Human Use S2(R1)". ICH Harmonised Tripartite Guideline, International Conference on Harmonization, Geneva, Switzerland, 2011.

Johnson, G. *et al.* (2014), "Derivation of point of departure (PoD) estimates in genetic toxicology studies and their potential applications in risk assessment", *Environmental and Molecular Mutagenesis*, Vol. 55/8, pp. 609-623.

Kim, B. *et al.* (2000), "Statistical analysis of *in vivo* rodent micronucleus assay", *Mutation Research*, Vol. 469/2, pp. 233-241.

Kirkland, D, and P Fowler. (2010), "Further analysis of Ames-negative rodent carcinogens that are only genotoxic in mammalian cells *in vitro* at concentrations exceeding 1 mM, including retesting of compounds of concern", *Mutagenesis*, Vol. 25/6, pp. 539-553.

Kirkland, D. *et al.* (2008), "Recommended lists of genotoxic and non-genotoxic chemicals for assessment of the performance of new or improved genotoxicity tests: A follow-up to an ECVAM workshop", *Mutation Research*, Vol. 653/1-2, pp. 99-108.

Kirkland, D. *et al.* (2007), "How to reduce false positive results when undertaking *in vitro* genotoxicity testing and thus avoid unnecessary follow-up animal tests: Report of an ECVAM Workshop", *Mutation Research*, Vol. 628/1, pp. 31-55.

Kirkland, D. and G Speit. (2008), "Evaluation of the ability of a battery of three *in vitro* genotoxicity tests to discriminate rodent carcinogens and non-carcinogens III. Appropriate follow-up testing *in vivo*", *Mutation Research*, Vol. 654/2, pp. 114-132.

Kissling, G. *et al.* (2007), "Sensitivity of the erythrocyte micronucleus assay: Dependence on number of cells scored and inter- animal variability", *Mutation Research*, Vol. 634/1-2, pp. 235-240.

Kligerman, A. *et al.* (1994), "Cytogenetic and germ cell effects of phosphine inhalation by rodents: II. Subacute exposures to rats and mice", *Environmental and Molecular Mutagenesis*, Vol. 24/4, pp. 301-306.

Lang, R. and I Adler. (1977), "Heritable translocation test and dominant--lethal assay in male mice with methyl methanesulfonate", *Mutation Research*, Vol. 48/1, pp.75-88.

Lemieux, C. *et al.* (2011), “Simultaneous measurement of benzo[a]pyrene-induced Pig-a and lacZ mutations, micronuclei and DNA adducts in Muta™ Mouse”, *Environmental and Molecular Mutagenesis*, Vol. 52/9, pp. 756-765.

Liber, H. L. *et al.* (1989), “A comparison of mutation induction at the TK and HPRT loci in human lymphoblastoid cells: Quantitative differences are due to an additional class of mutations at the autosomal TK locus”, *Mutation Research*, Vol. 216/1, pp. 9-17.

Lloyd, M. and D Kidd. (2012), “The mouse lymphoma assay”, *Methods in Molecular Biology*, Vol. 817, pp. 35-54.

Lorenzo, Y. *et al.* (2013), “The comet assay, DNA repair and cytotoxicity: *Hedgehogs are not dead*”, *Mutagenesis*, Vol. 28/4, pp. 427-432.

Lorge, E. *et al.* (2008), “Comparison of different methods for an accurate assessment of cytotoxicity in the *in vitro* micronucleus test. I. Theoretical aspects”, *Mutation Research*, Vol. 655/1-2, pp. 1-3.

Lorge, E. *et al.* (in prep), “Standardized cell sources and recommendations for good cell culture practices in genotoxicity testing”,

Lovell, D. *et al.* (1989), Chapter 7: “Statistical analysis of *in vivo* cytogenetic assays”, in *Statistical Evaluation of Mutagenicity Test Data (Part 3)*, D.J. Kirkland (Ed.), Cambridge University Press, Cambridge, United Kingdom, pp. 184-232.

Lovell, D. *et al.* (1987), “The use of a battery of strains of mice in a factorial design to study the induction of dominant lethal mutations”, *Mutation Research*, Vol. 187/1, pp. 37-44.

Luippold, H. *et al.* (1978), “The production of chromosome aberrations in various mammalian cells by triethylenemelamine”, *Genetics*, Vol. 88/2, pp. 317-326.

MacGregor, J. *et al.* (2015a), “IWGT report on quantitative approaches to genotoxicity risk assessment II. Use of point-of-departure (PoD) metrics in defining acceptable exposure limits and assessing human risk”, *Mutation Research/Genetic Toxicology and Environmental Mutagenesis*, Vol. 783, pp. 66-78.

MacGregor, J. *et al.* (2015b), “IWGT report on quantitative approaches to genotoxicity risk assessment I. Methods and metrics for defining exposure–response relationships and points of departure (PoDs)”, *Mutation Research/Genetic Toxicology and Environmental Mutagenesis*, Vol. 783, pp. 55–65.

Madrigal-Bujaidar, E. *et al.* (2008), “Micronuclei induced by imipramine and desipramine in mice: A subchronic study”, *Basic and Clinical Pharmacology and Toxicology*, Vol. 103/6, pp. 569-573.

Manjanatha, M. *et al.* (2015), “Evaluation of cII mutations in lung of male Big Blue mice exposed by inhalation to vanadium pentoxide for up to 8 weeks”, *Mutation Research/Genetic Toxicology and Environmental Mutagenesis*, Vol. 789-790, pp. 46-52.

Marchetti, F. *et al.* (2004), “Paternally transmitted chromosomal aberrations in mouse zygotes determine their embryonic fate”, *Biology of Reproduction*, Vol. 70/3, pp. 616-624

Mei, N. *et al.* (2014), Chapter 34: “Methods for using the mouse lymphoma assay to screen for chemical mutagenicity and photo-mutagenicity”, in *Optimization in Drug Discover: In Vitro Methods*, 2nd Edition, Caldwell, G. and Z Yan (eds), Humana Press, Totowa, New Jersey, pp. 561-592.

Miltenburger, H. *et al.* (1978), “The effect of isoniazid (INH) on Chinese hamster and mouse spermatogonia”, *Human Genetics*, Vol. 42/1, pp. 44-49.

Montgomery, D. (2005), “Introduction to statistical quality control”, 5th Edition. John Wiley & Sons, Inc, Hoboken, New Jersey.

Moore, M. and D. Clive. (1982), “The quantitation of TK^{-/-} and HGPRT⁻ mutants of L5178Y/TK^{+/-} mouse lymphoma cells at varying times post treatment”, *Environmental and Molecular Mutagenesis*, Vol. 4/4, pp. 499-519.

Moore, M. *et al.* (2000), “Mouse lymphoma thymidine kinase locus gene mutation assay: International Workshop on Genotoxicity Test Procedures Workgroup Report”, *Environmental and Molecular Mutagenesis*, Vol. 35/3, pp. 185-190.

Moore, M. *et al.* (2002), “Mouse lymphoma thymidine kinase gene mutation assay: Follow-Up International Workshop on Genotoxicity Test Procedures”, New Orleans, Louisiana, *Environmental and Molecular Mutagenesis*, Vol. 40/4, pp. 292-299.

Moore, M. *et al.* (2003), “Mouse lymphoma thymidine kinase gene mutation assay: International Workshop on Genotoxicity tests Workgroup report – Plymouth, UK 2002”, *Mutation Research*, Vol. 540(2), pp. 127-140.

Moore, M. *et al.* (2006), “Mouse Lymphoma Thymidine Kinase Gene Mutation Assay: Follow-up Meeting of the International Workshop on Genotoxicity Testing – Aberdeen, Scotland, 2003 – Assay acceptance criteria, positive controls, and data evaluation”, *Environmental and Molecular Mutagenesis*, Vol. 47/1, pp. 1-5.

Moore, M. *et al.* (2008), “Analysis of *in vivo* mutation data can inform cancer risk assessment”, *Regulatory Toxicology and Pharmacology*, Vol. 51/2, pp. 151-161.

Moore, M. *et al.* (2015), “Mutagenesis and Genetic Toxicology”, in *Principles of Toxicology: Environmental and Industrial Applications*, 3rd Edition, Williams, P. *et al.* (eds), John Wiley & Sons, Inc., pp.235-258.

Morita, T. *et al.* (2012), “Effect of reducing the top concentration used in the *in vitro* chromosomal aberration test in CHL cells on the evaluation of industrial chemical genotoxicity”, *Mutation Research*, Vol. 741/1-2, pp. 32-56.

Mullins, E. (2003), “Statistics for the quality control chemistry laboratory”, The Royal Society of Chemistry, Cambridge.

OECD (1987), “Introduction to the OECD Guidelines on Genetic Toxicology Testing and Guidance on the Selection and Application of Assays”, in the Third Addendum to the OECD Guidelines for Testing of Chemicals (10th edition). OECD Publications, Paris.

OECD (2000), “Guidance document on the recognition, assessment and use of clinical signs as humane endpoints for experimental animals used in safety evaluation”, OECD Environmental Health and Safety Publications, Series on Testing and Assessment, No. 19, Paris, ENV/JM/MONO(2000)7.

OECD (2009), “Detailed review paper on transgenic rodent mutation assays”, OECD Environmental Health and Safety Publications, Series on Testing and Assessment, No. 103, Paris, ENV/JM/MONO 7.

OECD. (1986), *Test No. 485: Genetic toxicology, Mouse Heritable Translocation Assay*, OECD Guidelines for the Testing of Chemicals, Section 4, OECD Publishing, Paris.

OECD. (1997a), *Test No. 471: Bacterial Reverse Mutation Test*, OECD Guidelines for the Testing of Chemicals, Section 4, OECD Publishing, Paris.

OECD. (1997b), *Test No. 486: Unscheduled DNA Synthesis (UDS) Test with Mammalian Liver Cells in vivo*, OECD Guidelines for the Testing of Chemicals, Section 4, OECD Publishing, Paris.

OECD. (2013), *Test No. 488: Transgenic Rodent Somatic and Germ Cell Gene Mutation Assays*, OECD Guidelines for the Testing of Chemicals, Section 4, OECD Publishing, Paris.

OECD. (2014a), *Test No. 473: In Vitro Mammalian Chromosomal Aberration Test*, OECD Guidelines for the Testing of Chemicals, Section 4, OECD Publishing, Paris.

OECD. (2014b), *Test No. 474: Mammalian Erythrocyte Micronucleus Test*, OECD Guidelines for the Testing of Chemicals, Section 4, OECD Publishing, Paris.

OECD. (2014c), *Test No. 475: Mammalian Bone Marrow Chromosomal Aberration Test*, OECD Guidelines for the Testing of Chemicals, Section 4, OECD Publishing, Paris.

OECD. (2014d), *Test No. 487: In Vitro Mammalian Cell Micronucleus Test*, OECD Guidelines for the Testing of Chemicals, Section 4, OECD Publishing, Paris.

OECD. (2014e), *Test No. 489: In Vivo Mammalian Alkaline Comet Assay*, OECD Guidelines for the Testing of Chemicals, Section 4, OECD Publishing, Paris.

OECD. (2014f), "Report on statistical issues related to OECD test guidelines (TGs) on genotoxicity", OECD Environmental Health and Safety Publications, Series on Testing and Assessment, No. 198, OECD Publishing, Paris, ENV/JM/MONO(2014)12.

OECD. (2015a), *Test No. 476: In Vitro Mammalian Cell Gene Mutation Tests using the Hprt and xprt genes*, OECD Guidelines for the Testing of Chemicals, Section 4, OECD Publishing, Paris.

OECD. (2015b), *Test No. 478: Rodent Dominant Lethal Test*, OECD Guidelines for the Testing of Chemicals, Section 4, OECD Publishing, Paris.

OECD. (2015c), *Test No. 483: Mammalian Spermatogonial Chromosomal Aberration Test*, OECD Guidelines for the Testing of Chemicals, Section 4, OECD Publishing, Paris.

OECD. (2015d), *Test No. 490: In Vitro Mammalian Cell Gene Mutation Tests Using the Thymidine Kinase Gene*, OECD Guidelines for the Testing of Chemicals, Section 4, OECD Publishing, Paris.

Palo, A. *et al.* (2005), "Etoposide-induced cytogenotoxicity in mouse spermatogonia and its potential transmission", *Journal of Applied Toxicology*, Vol. 25/2, pp. 94-100.

Palo, A. *et al.* (2009), "Cytosine arabinoside-induced cytogenotoxicity in bone marrow and spermatogonial cells of mice and its potential transmission through the male germline", *Mutation Research*, Vol. 673/1, pp. 29-36.

Palo, A. *et al.* (2011), “Vinblastine-induced cytogenotoxicity in spermatogonia and its transmission in the germline cells of Swiss mice”, *Journal of Environmental, Pathology, Toxicology, and Oncology*, Vol. 30/2, pp. 113-121.

Parsons, B. *et al.* (2013), “Temporal changes in K-ras mutant fraction in lung tissue of big blue B6C3F₁ mice exposed to ethylene oxide”, *Toxicological Sciences*, Vol. 136/1, pp. 26-38.

Parry, J. *et al.* (2010), “Analysis of published data for top concentration considerations in mammalian cell genotoxicity testing”, *Mutagenesis*, Vol. 25/6, pp. 531-538.

Pfuhler, S. *et al.* (2009), “Reduction of use of animals in regulatory genotoxicity testing: Identification and implementation opportunities- Report from an ECVAM workshop”, *Mutation Research*, Vol. 680/1-2, pp. 31-42.

Rao, U. *et al.* (1994), “Studies on the effect of ethanol on dominant lethal mutations in Swiss, C57BL6 and CBA mice”, *Mutation Research*, Vol. 311/1, pp. 69-76.

Rathenberg, R. (1975), “Cytogenetic effects of cyclophosphamide on mouse spermatogonia”, *Humangenetik*, Vol. 29/2, pp. 135-140.

Rothfuss, A. *et al.* (2011), “Improvement of *in vivo* genotoxicity assessment: combination of acute tests and integration into standard toxicity testing”, *Mutation Research*, Vol. 723/2, pp. 108-120.

Russell, W. and R Burch. (1959), “The principles of humane experimental technique”, John Hopkins Bloomberg School of Public Health, Methuen, London.

Ryan, T. (2000), “Statistical Methods for Quality Improvement”, 2nd edition. John Wiley and Sons, Inc., New York.

Ryan, T. (2011), “Statistical Methods for Quality Improvement”, 3rd edition. John Wiley and Sons, Inc., New York.

Schisler, M. *et al.* (2013), Chapter 2: “*In vitro* mouse lymphoma (L5178Y TK+/-3.7.2C) forward mutation assay”, in *Genotoxicity Assessment: Part I, Methods and Protocols*, Dhawan, A. and M Bajpayee (eds.), Humana Press, New York City, pp. 27-50.

Scott, D. *et al.* (1991), “International Commission for Protection against Environmental Mutagens and Carcinogens. Genotoxicity under extreme culture conditions. A report from ICPEMC Task Group 9”, *Mutation Research*, Vol. 257/2, pp. 147–205.

Seager, A. *et al.* (2014), “Recommendations, evaluation and validation of a semi-automated, fluorescent-based scoring protocol for micronucleus testing in human cells”, *Mutagenesis*, Vol. 29/3, pp. 155-164.

Shelby, M. *et al.* (1991), “Mouse dominant lethal and bone marrow micronucleus studies on methyl vinyl sulfone and divinyl sulfone”, *Mutation Research*, Vol. 250/1-2, pp. 431-437.

Shelby, M. *et al.* (1986), “Dominant lethal effects of acrylamide in male mice”, *Mutation Research*, Vol. 173/1, pp. 35-40.

Slatter, M. and A Gennery. (2010), “Primary immunodeficiencies associated with DNA-repair disorders”, *Expert Reviews in Molecular Medicine*, Vol. 12, pp. e9.

Smith, C. *et al.* (2008), "Recommendations for design of the rat comet assay", *Mutagenesis*, Vol. 23/3, pp. 233-40.

Speit, G. *et al.* (2015), "Critical issues with the *in vivo* comet assay: a report of the comet assay working group in the 6th International Workshop on Genotoxicity Testing (IWGT)", *Mutation Research/Genetic Toxicology and Environmental Mutagenesis*, Vol. 783, pp. 6-12.

Styles, J. *et al.* (2001), "Automation of mouse micronucleus genotoxicity assay by laser scanning cytometry", *Cytometry*, Vol. 44/2, pp. 153-155.

Sudman, P. *et al.* (1992), "Bleomycin: female-specific dominant lethal effects in mice", *Mutation Research*, Vol. 296/1-2, pp. 143-156.

Sui, H. *et al.* (2009), "Improvement and evaluation of high throughput fluctuation Ames test using 384-well plate with *Salmonella typhimurium* TA100 and TA98", *Genes and Environment* Vol. 31, pp. 47-55.

Tates, A. and A Natarajan. (1976), "A correlative study on the genetic damage induced by chemical mutagens in bone marrow and spermatogonia of mice. I. CNU-ethanol", *Mutation Research*, Vol. 37/2-3, pp. 267-278.

Thybaud, V. *et al.* (2003), "*In vivo* transgenic mutation assays", *Mutation Research*, Vol. 540/2, pp. 141-151.

Thybaud, V. *et al.* (2007), "Expert working group on hazard identification and risk assessment in relation to *in vitro* testing. Strategy for genotoxicity testing: Hazard identification and risk assessment in relation to *in vitro* testing", *Mutation Research*, Vol. 627/1, pp. 41-58.

Thybaud, V. *et al.* (2011), "Strategies in case of positive *in vivo* results in genotoxicity testing", *Mutation Research*, Vol. 723/2, pp. 121-128.

Tice, R. *et al.* (1990), "The single cell gel assay: A sensitive technique for evaluating intercellular differences in DNA damage and repair", *Basic Life Sciences*, Vol. 53, pp. 291-301.

Torous, D. *et al.* (2000), "Enumeration of micronucleated reticulocytes in rat 1 peripheral blood: a flow cytometric study", *Mutation Research*, Vol. 465/1-2, pp. 91-99.

Tweats, D. *et al.* (2007a), "Report of the IWGT working group on strategies and interpretation of regulatory *in vivo* tests I. Increases in micronucleated bone marrow cells in rodents that do not indicate genotoxic hazards", *Mutation Research*, Vol. 627/1, pp. 78-91.

Tweats, D. *et al.* (2007b), "Report of the IWGT working group on strategies and interpretation of regulatory *in vivo* tests II. Identification of *in vivo*-only positive compounds in the bone marrow micronucleus test", *Mutation Research*, Vol. 627/1, pp. 92-105.

van Buul, P. and J Goudzwaard. (1980), "Bleomycin-induced structural chromosomal aberrations in spermatogonia and bone-marrow cells of mice", *Mutation Research*, Vol. 69/2, pp. 319-324.

Wang, J. *et al.* (2009), "The mouse lymphoma assay detects recombination, deletion, and aneuploidy", *Toxicological Sciences*, Vol. 109/1, pp. 96-105.

Witt, K. *et al.* (2003), "Mouse bone marrow micronucleus test results do not predict the germ cell mutagenicity of N-hydroxymethylacrylamide in the mouse dominant lethal assay", *Environmental and Molecular Mutagenesis*, Vol. 41/2, pp. 111-120.

Witt, K. *et al.* (2000), "Micronucleated erythrocyte frequency in peripheral blood of B6C3F(1) mice from short-term, prechronic, and chronic studies of the NTP carcinogenesis bioassay program", *Environmental and Molecular Mutagenesis*, Vol. 36/3, pp. 163-194.

Yauk, C. *et al.* (2015), "Approaches for identifying germ cell mutagens: Report of the 2013 IWGT Workshop on germ cell assays", *Mutation Research*, Vol. 783, pp. 36-54.

Uno, Y. *et al.* (2015a), "Recommended protocols for the liver micronucleus test: Report of the IWGT working group", *Mutation Research*, Vol. 783, pp. 13-18.

Uno, Y. *et al.* (2015b), "Micronucleus test in rodent tissues other than liver or erythrocytes: Report of the IWGT working group", *Mutation Research*, Vol. 783, pp. 19-22.

Zhang, H. *et al.* (1998), "Chromosomal aberrations induced by $^{12}\text{C}^{6+}$ heavy ion irradiation in spermatogonia and spermatocytes of mice", *Mutation Research*, Vol. 398/1-2, pp. 27-31.

Zhang, H. *et al.* (2008), "Induction of cytogenetic adaptive response in spermatogonia and spermatocytes by pre-exposure of mouse testis to low dose $^{12}\text{C}^{6+}$ ions", *Mutation Research*, Vol. 653/1-2, pp. 109-112.

APPENDIX A. DOCUMENT SUPPORTING THE WNT DECISION TO IMPLEMENT REVISED CRITERIA FOR THE SELECTION OF THE TOP CONCENTRATION IN THE IN VITRO MAMMALIAN CELL ASSAYS ON GENOTOXICITY (TEST GUIDELINES 473, 476 AND 487) - [ENV/JM/TG/RD(2014)20]

The Impact of the Top Concentration on the Sensitivity and the Specificity of the Assay

INTRODUCTION AND BACKGROUND


1. In the previous version of OECD Test Guidelines (TGs) for *in vitro* mammalian genotoxicity, the top concentration for soluble compounds in the absence of cytotoxicity was 10 mM or 5000 µg/mL, whichever is lower. This top concentration was selected originally because it was considered to be the highest concentration that induces no extremes of osmolarity and pH, with the concern that changes in osmolarity and pH would induce artefacts/misleading positive results in mammalian cells.
2. This rationale for the top concentration was challenged as early as a decade ago. It was suggested that at such high concentrations the mammalian cell metabolism mediated through enzymes would be overwhelmed; for example, as most enzyme Km are below 100 µM, higher concentrations could result in non-physiological effects. It was thought that in this way misleading positive results may be generated. Accordingly, it is possible that such positive results may require further, possibly unnecessary, *in vivo* testing. In response to this issue, the OECD undertook to revise the top concentration criteria to improve the specificity of the mammalian tests without losing sensitivity for the *in vitro* Test Guidelines that are under revision.
3. An OECD expert group (EG) on genotoxicity discussed this issue in 2011 and 2012, and a large majority of experts agreed on a reduced top concentration of 10 mM or 2000 µg/mL, whichever is lower¹. However, the 5000 µg/mL limit is maintained for mixtures. This recommendation was approved subsequently by the WNT at its 24th meeting in April 2012. However, Japan strongly recommended that a document be developed to provide information on the specificity and the sensitivity for *in vitro* mammalian genotoxicity assays using the new top concentration rather than the new ICH recommendation (S2(R1)).
4. Studies using different data sets and different approaches have attempted to quantify the sensitivity and, to a much lesser extent, specificity of the tests using different top concentrations and to make comparisons between them. Although most of these analyses used data from chromosomal damage assays, the EG agreed that results and conclusions from such analyses should apply to all *in vitro* mammalian cell assays. Two publications (Morita *et al.*, 2012, and Brookmire *et al.*, 2013) were found to be particularly useful for the analysis presented in the sections below.
5. The ICH guideline S2(R1) recommends a maximum top concentration of 1 mM or 500 µg/mL, whichever is lower when not limited by solubility in solvent or culture medium or by cytotoxicity. However, for pharmaceuticals with unusually low molecular weight, that is, less than 200 Da, higher test concentrations should be considered (ICH S2(R1) Footnote 2). The ICH Footnote 2) wording does not specify an upper concentration limit. Accordingly, in the analysis below it was assumed (based on the expert recommendation of pharmaceutical regulators), that the “WNT

¹ For brevity, herein the WNT-approved OECD Top Concentration Criteria are referred to as “WNT-approved OECD Criteria”

approved OECD top concentration criteria” would apply, by default, to chemicals covered by Footnote 2).

6. While pharmaceuticals with molecular weights less than 200 Da are relatively rare, such is not the case with the chemicals covered by OECD TGs (*e.g.* the majority of chemicals in Morita *et al.* (2012)). Furthermore, a high proportion of the IARC human carcinogens have a relatively low molecular weight (Fig. 1). Such information further indicates the need for a top concentration scheme that deals adequately with such lower molecular weight chemicals.

Fig. 1. Molecular Weight Distribution of 48 IARC Group 1 Carcinogens



SENSITIVITY AND SPECIFICITY OF THE ASSAY

Analysis of Sensitivity

7. Brookmire *et al.* (2013) examined the concentration-response curves for the same *in vitro* CA assay data as used by Parry *et al.* (2010) (which included only carcinogenic chemicals, and therefore, does not permit an analysis of specificity). They determined the lowest concentration at which CAs were detected for each compound and they analysed with these concentrations the sensitivity of the CA assay, and the fraction of compounds that would not be detected as positive as a function of the top concentration limit selected for the assay. The results of this study indicate that a top concentration of 5000 µg/mL detects 99% of rodent carcinogens. Setting the top concentration between 1000 and 2000 µg/mL would detect 95% of rodent carcinogens, equivalent to the fraction detected by using a top concentration of 10 mM. Therefore, if a lower µg/mL concentration is sought to pair with 10 mM, 2000 µg/mL is better aligned with 10 mM than to 5000 µg/mL, based on CA test performance. They pointed out that this approach treats data equally across the entire concentration response curve, as opposed to analyses that conduct intensive analyses only of compounds at the high end of the concentration response curve. A flaw in the latter approach is that one does not know the frequency with which compounds detected in the assay at lower concentrations would be considered of lower concern.
8. Morita *et al.* (2012) analysed 249 high production volume (HPV) chemicals tested in the *in vitro* CA test with CHL cells in accordance with Japanese or OECD Test Guidelines. 38 chemicals that were positive for CAs at >1 mM, but negative at ≤1 mM and also negative in the Ames test were identified. These are chemicals that would be missed in the standard genotoxicity test battery if the highest concentration tested in mammalian cells was lowered to 1 mM.
9. The level of concern for human health risk was assessed for these 38 “missed” chemicals based on a weight of evidence approach which included the following: evaluation of the effects of extreme culture conditions (low pH, high toxicity, or precipitation); *in silico* structural alert analysis; *in vivo* genotoxicity and carcinogenicity test data; mode of action or information from closely related chemicals. After an exhaustive review, four chemicals with “some concern”, nine with “minimal concern”, and remaining 25 with “negligible concern” were identified. This holistic approach for the prediction of *in vivo* outcomes, makes the best use of the available information, when data (in particular carcinogenicity data) for a full risk assessment are not available. However, such an approach can sometimes rely on broad assumptions when direct supporting data are not available. Furthermore, it should be noted that the 38 chemicals of Morita *et al.* (2012), which were used to determine the sensitivity and specificity² of various top concentration proposals, and used subsequently herein in Tables 1 and 3 all have Lowest Effective Concentrations (LECs) for the CA assay at 1 mM or above, and as such may result in outcomes that are not fully representative of all chemicals.
10. Many top concentration limit options were discussed by the EG at their meeting in January 2012. The table below presents the various options, including the rationale behind each option.

² The sensitivity is thus defined in the rest of the report as the ability of the test to predict (in case of a positive result) concern (“some” or “minimal” concern as defined by Morita *et al.*, 2012) for human health based on a weight of evidence approach. The specificity is defined as the ability of the test to predict (in case of a negative result) “negligible” concern for human health (as defined by Morita *et al.*, 2012).

Table 1. Summary of the different scenarios and options suggested during EG meeting in January 2012

Options	Name	Suggested values	Rationale
Option 1	called “OECD”	10 mM or 5000 µg/mL, whichever is lower	Current criteria
Option 2	called “ICH”	1 mM or 500 µg/mL, whichever is lower,	Currently suggested in ICH S2(R1) for pharmaceuticals
Option 3	called “DK”	1 mM or 500 µg/mL, whichever is higher,	Mostly based on re-analysis of NTP database and recent experiments (Fowler and Kirkland, 2010).
Option 4	called “BG”	10 mM or 1000 µg/mL, whichever is lower,	Based on extrapolation made from the use of 1000 mg/kg <i>in vivo</i> , and the need to test higher concentrations for low molecular weight compounds
Option 5	called “BG-GD”	10 mM or 2000 µg/mL, whichever is lower,	Based on extrapolation made from the use of 2000 mg/kg <i>in vivo</i> for short term treatment, and the need to test higher concentrations for low molecular weight compounds In addition 2000 µg/mL is better aligned with 10 mM than to 5000 µg/mL, based on CA test performance (Brookmire et al., 2013)
Option 6	called “VTEL”	4 mM alone when molecular weight is known, and 2000 µg/mL, when molecular weight is unknown	Compromise that takes all other options into account, relies on molarity only except when no information is available on molecular weight, applies a 2.5 fold reduction to the current top concentration, and a 4-fold safety factor to “DK” proposal (based on the analysis of existing data)
Option 7	called “Alternative VTEL” (AVTEL)	4 mM or 2000 µg/mL, whichever is lower	VTEL proposal with a “cap” at 2000 µg/mL to avoid very high concentration in µg/mL for high molecular weight molecules.

11. In Morita *et al.* (2012) paper, several of these top concentration limits were applied to the 38 chemicals mentioned in paragraph 8:

- 1mM or 0.5 mg/ml, whichever is higher
- 2 mM or 1 mg/mL, whichever is higher,
- 4mM or 2 mg/mL, whichever is lower
- 10 mM or 2 mg/mL whichever is lower.

Results of the analysis are shown in Annex 1.

12. In Tables 1 and 3 below, the newly adopted ICH S2(R1) and the “WNT-approved OECD top concentrations” are applied to the 38 “missed” chemicals from the study from Morita *et al.* (2012) in an analysis of the relative sensitivity and specificity of the two different top concentrations. For the ICH approach, the “WNT-approved OECD criteria” were applied for substances with a MW below 200 Da as per Footnote 2. Those 13 chemicals with “some” or “minimal” concern have been considered to be “real positives”; that is, ideally they would be detected as positive in the CA tests. By contrast, the 25 chemicals of “negligible” concern have been considered as “real

negatives” and ought not be detected as positive; a positive response for these tests would be considered a “misleading positive” result.

Table 1. *In vitro* CA test outcomes for the 13 Ames test negative chemicals of concern (compounds of “minimal” and “some” concern; Morita *et al.*, 2012) using: (1) ICH top concentration (*i.e.* 1 mM or 500 µg/mL whichever is lower) with the “WNT-approved OECD criteria” (10 mM or 2000 µg/mL whichever is lower) for chemicals with MW below 200 and (2) the “WNT-approved OECD criteria” (*i.e.* 10mM or 2000 µg/ml (whichever is lower) is applied for all MWs)

ID (see Morita <i>et al.</i> , 2012 for CAS number and chemical name)	MW	LEC (mM)	LEC (µg/mL)	(1) Detected when ICH criteria are applied (WNT-approved OECD criteria for MW below 200)	(2) Detected when WNT-approved OECD criteria are applied
84	116.1	10.0	1200	yes	yes
86	239.3*	2.5	600	no	yes
90	121.2	9.1	1100	yes	yes
95	784.1*	3.2	2500**	no	no
100	148.2	5.0	800	yes	yes
102	1347.1*	3.7	5000**	no	no
104	258.4*	2.5	700	no	yes
106	135.2	3.8	400	yes	yes
110	71.1	10.0	700	yes	yes
111	150.2	5.3	800	yes	yes
112	107.2	5.5	600	yes	yes
115	124.1	10.0	1200	yes	yes
116	59.1	6.4	400	yes	yes
# positive/13				9	11
# misleading negatives/13				4	2
Sensitivity				69%	85%

LEC: Lowest Effective Concentration

* Chemicals with MW > 200

**Chemicals with LEC > 2000 µg/ml

13. As indicated in Table 1, the sensitivity of the CA test for the Ames test negative chemicals of concern is improved from 69% to 85% when the “WNT-approved OECD criteria” are applied rather than the ICH criteria (with Footnote 2 as described above for the lower than 200 Da compounds).
14. Based on the extensive analysis of Brookmire *et al.* (2013), it is clear that the LECs for *in vitro* cytogenetic positives are not different for chemicals that are positive or negative in the Ames test. Therefore, it is appropriate to also evaluate the LEC and top concentration for the 13 *in vitro* CA test chemicals that are positive between 1mM and 10 mM and are also positive in the Ames test (Table 2). The results are similar to those of the Ames test negative chemicals; the sensitivity for the “WNT-approved OECD criteria” is 92% while the ICH recommendation is 69%.

Table 2. *In vitro* CA test outcomes for the 13 Ames test positive chemicals (Morita *et al.*, 2012) using: (1) ICH top concentration (*i.e.* 1 mM or 500 µg/mL whichever is lower) with the “WNT-approved OECD criteria” (10 mM or 2000 µg/mL whichever is lower) for chemicals with MW below 200 and (2) the “WNT-approved OECD criteria” (*i.e.* 10mM or 2000 µg/ml (whichever is lower) is applied for all MWs)

ID (see Morita <i>et al.</i> , 2012 for CAS number and chemical name)	MW	LEC (mM)	LEC (µg/mL)	(1) Detected when ICH criteria are applied (WNT-approved OECD criteria for MW below 200)	(2) Detected when WNT-approved OECD criteria are applied
66	104.2	9.6	1000	yes	yes
67	223.3*	4.9	1100	no	yes
68	157.4	1.6	300	yes	yes
69	157.2	4.0	600	yes	yes
70	121.2	5.0	600	yes	yes
71	121.2	2.5	300	yes	yes
72	121.2	7.4	900	yes	yes
73	580.1*	4.3	2500**	no	no
74	123.2	6.1	800	yes	yes
75	358.4*	1.6	600	no	yes
76	108.1	5.5	600	yes	yes
77	174.2	1.8	300	yes	yes
78	229.1*	7.0	1600	no	yes
# positive/13				9	12
# misleading negatives/13				4	1
Sensitivity				69%	92%

LEC: Lowest Effective Concentration

* Chemicals with MW > 200

**Chemicals with LEC > 2000 µg/ml

Analysis of Specificity

15. The analysis from Brookmire *et al.* (submitted) does not address the specificity of the CA assay. However, the results for specificity as determined by the ICH top concentration with the “WNT-approved OECD criteria” for MW below 200, and the “WNT-approved OECD criteria” based on the data from Morita *et al.* (2012) are provided in the Table 3 below. The specificity determined by the “WNT-approved OECD criteria” is lower than the specificity using the ICH criteria for this selection of chemicals.

Table 3. *In vitro* CA test outcomes for the 25 Ames test negative chemicals of “negligible” concern using (Morita *et al.*, 2012): (1) ICH top concentration (*i.e.* 1 mM or 500 µg/mL whichever is lower) with the “WNT-approved OECD criteria” (10 mM or 2000 µg/mL whichever is lower) for chemicals with MW below 200 and (2) the “WNT-approved OECD criteria” (*i.e.* 10 mM or 2000 µg/ml (whichever is lower) is applied for all MWs)

ID (see Morita <i>et al.</i> , 2012 for CAS number and chemical name)	MW	LEC (mM)	LEC (µg/mL)	(1) Detected when ICH criteria are applied (WNT-approved OECD criteria for MW below 200)	(2) Detected when WNT-approved OECD criteria are applied.
79	173.2	2.4	400	yes	yes
80	221.5*	9.0	2000	no	yes
81	187.2	5.1	1000	yes	yes
82	218.2*	10.0	2200**	no	no
83	138.1	5.1	700	yes	yes
85	186.2	9.1	700	yes	yes
87	142.2	2.8	400	yes	yes
88	147.0	1.6	200	yes	yes
89	181.3	3.3	600	yes	yes
91	130.2	5.0	700	yes	yes
92	136.2	8.8	1200	yes	yes
93	317.9*	6.3	2000	no	yes
94	250.3*	1.6	400	no	yes
96	128.1	2.5	300	yes	yes
97	185.3	3.2	600	yes	yes
98	144.2	5.0	700	yes	yes
99	207.7*	10.0	2100**	no	no
101	128.6	2.0	300	yes	yes
103	235.9*	2.3	600	no	yes
105	173.3	1.9	300	yes	yes
107	184.1	6.5	200	yes	yes
108	116.2	3.4	400	yes	yes
109	278.0*	1.8	500	no	yes
113	161.1	3.8	600	yes	yes
114	430.6*	2.5	1100	no	yes
# negative/25				8	2
# potential misleading positives/25				17	23
Specificity				32%	8%

LEC: Lowest Effective Concentration

* Chemicals with MW > 200

**Chemicals with LEC > 2000 µg/ml

The “WNT-approved OECD criteria” resulted in a reduction in specificity compared to the ICH (with Footnote 2) of 32% to 8%.

Conclusions

16. For the chemicals studied in Morita *et al.* (2012) (of which ~80% have molecular weights below 200), detection of chemicals of concern (*i.e.* sensitivity) is 9/13 for ICH *versus* 11/13 for “WNT-approved OECD criteria”; detection of compounds of negligible concern (*i.e.* specificity) is 17/25 for ICH *versus* 23/25 for “WNT-approved OECD criteria” (*i.e.* from 8/25 accurately detected as negative to 2/25 accurately detected as negative). Thus, there is a marked increase in sensitivity from 69% to 85% by using “WNT-approved OECD criteria” rather than ICH top concentration limits. This outcome is balanced by a concomitant decrease in specificity from 32% to 8%, respectively. These specificity values are low when either ICH (for chemicals with MW less than 200) or “WNT-approved OECD criteria” are used, but the deterioration in specificity is not considered a major problem in light of: (a) the limited specificity in any case using ICH criteria; (b) the marked increase in sensitivity.
17. The conclusion in the Morita *et al.* paper is that the top concentration of 2 mM or 1 mg/mL, whichever is higher, is most effective, *i.e.*, relatively higher (8/13) or lower (17/25) detection among 13 or 25 chemicals, respectively, the other top concentrations showing less response to one or both group of chemicals.
18. However, the “WNT-approved OECD criteria” was supported by the EG members as they considered that, for industrial chemicals, for which negative *in vitro* results might not be followed by further testing the most prudent course for public health is to maximize the sensitivity of the *in vitro* test battery and thus maximise the sensitivity of each single test included in the test battery. The drawback of maximizing the sensitivity of a test is at the expense of a lower specificity as demonstrated by Morita *et al.* 2012. However, the EG members consideration was that the most important issue was to obtain a higher sensitivity of the test. This is in contrast to pharmaceuticals that are almost always evaluated *in vivo*.
19. Strategies for following up a positive result in the *in vitro* test battery vary widely, primarily because the risk assessments for different regulatory programs diverge once data from the *in vitro* screening battery are collected. Once the sensitivity of the assay to the intended endpoint is known, this information can be used in a risk assessment tailored to risk/benefit analysis appropriate to the specific test article being evaluated. An advantage of having a sensitive initial screen is that it permits generation of the potentially relevant data while preserving options for follow-up based on the specific needs of the ensuing risk assessment (Brookmire *et al.*, 2013).

References

- Parry JM, Parry E, Phrakonkham P, Corvi R (2010), Analysis of published data for top concentration considerations in mammalian cell genotoxicity testing. *Mutagenesis*. 25:531-8
- Morita,T., M. Honma, K. Morikawa (2012), Effect of reducing the top concentration used in the in vitro chromosomal aberration test in CHL cells on the evaluation of industrial chemical genotoxicity, *Mutation research* 741:32-56.
- Brookmire L., J. Chen, R. Gudi and D.D. Levy (2013). Evaluation of the highest concentrations used in the chromosome aberrations assay. *Environmental and Molecular Mutagenesis* 54: 36-43.
- ICH Harmonised Tripartite Guideline (2011), International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use - Guidance on genotoxicity testing and data interpretation for pharmaceuticals intended for human use S2(r1), Current Step 4 version dated 9 November 2011.
- Kirkland D and Fowler P. (2010) Further analysis of Ames-negative rodent carcinogens that are only genotoxic in mammalian cells at concentrations exceeding 1 mM, including retesting of compounds of concern. *Mutagenesis* 25:539-553.

Annex 1

Application of Different Top Concentrations to 38 Missed Chemicals (from Morita et al., 2013)

Application of different top concentrations to 38 missed chemicals (13 with minimal or some concern and 25 with negligible concern).

ID no.	Chemical name	CAS	MW	LEC (mM)	LEC (mg/mL)	Detection at different top concentration limit			
						1 mM or 0.5 mg/mL, whichever is higher	2 mM or 1 mg/mL, whichever is higher	4 mM or 2 mg/mL, whichever is lower	10 mM or 2 mg/mL, whichever is lower
13 missed chemicals with minimal or some concern									
84	Methyl acetoacetate	105-45-3	116.1	10.0	1.2	No	No	No	Yes
86	1,3-Bis(2-methylphenyl)guanidine	97-39-2	239.3	2.5	0.6	No	Yes	Yes	Yes
90	<i>N</i> -Ethylaniline	103-69-5	121.2	9.1	1.1	No	No	No	Yes
95	1,3,5-Tris(3,5-di- <i>tert</i> -butyl-4-hydroxybenzyl)isocyanuric acid	27676-62-6	784.1	3.2	2.5	No	No	No	No
100	Ethenyltrimethoxysilane	2768-02-7	148.2	5.0	0.8	No	Yes	No	Yes
102	C.I. Fluorescent brightener 271	41267-43-0	1347.1	3.7	5.0	No	No	No	No
104	Dibutyl adipate	105-99-7	258.4	2.5	0.7	No	Yes	Yes	Yes
106	<i>N,N</i> -Dimethylberzylamine	103-83-3	135.2	3.8	0.4	Yes	Yes	Yes	Yes
110	2-Hydroxypropanenitrile	78-97-7	71.1	10.0	0.7	No	Yes	No	Yes
111	2-Mercaptobenzimidazole	583-39-1	150.2	5.3	0.8	No	Yes	No	Yes
112	<i>N</i> -Methylaniline	100-61-8	107.2	5.5	0.6	No	Yes	No	Yes
115	Trimethoxyphosphine	121-45-9	124.1	10.0	1.2	No	No	No	Yes
116	Trimethylamine	75-50-3	59.1	6.4	0.4	Yes	Yes	No	Yes
	Number of chemicals detected among the 13 chemicals					2	8	3	11
25 missed chemicals with negligible concern									
79	3-Aminobenzenesulfonic acid	121-47-1	173.2	2.4	0.4	Yes	Yes	Yes	Yes
80	2-Amino-5-chloro-4-methylbenzenesulfonic acid	88-53-9	221.5	9.0	2.0	No	No	No	Yes
81	2-Amino-5-methylbenzenesulfonic acid	88-44-8	187.2	5.1	1.0	No	Yes	No	Yes
82	Glycerol triacetate	102-76-1	218.2	10.0	2.2	No	No	No	No
83	4-Hydroxybenzoic acid	99-96-7	138.1	5.1	0.7	No	Yes	No	Yes
85	1-Naphthylacetic acid	86-87-3	186.2	9.1	1.7	No	No	No	Yes
87	<i>tert</i> -Butyl methacrylate	585-07-0	142.2	2.8	0.4	Yes	Yes	Yes	Yes
88	<i>o</i> -Dichlorobenzene	95-50-1	147.0	1.6	0.2	Yes	Yes	Yes	Yes
89	Dicyclohexylamine	101-83-7	181.3	3.3	0.6	No	Yes	Yes	Yes
91	2-Hydroxyethyl methacrylate	868-77-9	130.2	5.0	0.7	No	Yes	No	Yes
92	4-Methylbenzoic acid	99-94-5	136.2	8.8	1.2	No	No	No	Yes
93	Triphosphoric acid aluminium salt	13939-25-8	317.9	6.3	2.0	No	No	No	Yes
94	4,4'-Sulfonyldiphenol	80-09-1	250.3	1.6	0.4	Yes	Yes	Yes	Yes
96	1,2-Dicyanobenzene	91-15-6	128.1	2.5	0.3	Yes	Yes	Yes	Yes
97	2-(Diethylamino)ethyl methacrylate	105-16-8	185.3	3.2	0.6	No	Yes	Yes	Yes
98	Methacrylic acid, monoester with propane-1,2-diol	27813-02-1	144.2	5.0	0.7	No	Yes	No	Yes
99	(Methacryloyloxyethyl) trimethylammonium chloride	5039-78-1	207.7	10.0	2.1	No	No	No	No
101	2-Chlorophenol	95-57-8	128.6	2.0	0.3	Yes	Yes	Yes	Yes
103	1,4-Dibromobenzene	106-37-6	235.9	2.3	0.6	No	Yes	Yes	Yes
105	2-(Di- <i>n</i> -butylamino)ethanol	102-81-8	173.3	1.9	0.3	Yes	Yes	Yes	Yes
107	2,4-Dinitrophenol	51-28-5	184.1	6.5	1.2	No	No	No	Yes
108	2-Ethylbutyric acid	88-09-5	116.2	3.4	0.4	Yes	Yes	Yes	Yes
109	Ferrous sulfate heptahydrate	7782-63-0	278.0	1.8	0.5	Yes	Yes	Yes	Yes
113	<i>p</i> -Nitrophenol sodium salt	824-78-2	161.1	3.8	0.6	No	Yes	Yes	Yes
114	Sorbitan monooleate	1338-41-6	430.6	2.5	1.1	No	No	Yes	Yes
	Number of chemicals detected among the 25 chemicals					9	17	14	23

APPENDIX B. TREATMENT AND SAMPLING TIMES FOR IN VIVO GENETIC TOXICOLOGY TGS IN RODENTS (THE APPLICABLE TGS SHOULD BE CONSULTED FOR MORE DETAILED INFORMATION).

Test	Treatment	Sampling	
TG 474 (mammalian erythrocyte micronucleus):	Single	Bone Marrow: at least 2x, 24 - 48 hr after treatment	Peripheral Blood: at least 2x, 36 - 72 hr after treatment
	2 daily	BM: once 18 - 24 hr after treatment	PB: at least once 36 -48 hr after treatment
	3 or more daily	BM: 24 hr after treatment	PB: no later than 40 hr after treatment
TG 475 (mammalian bone marrow chromosome aberration):	Single	2x: first; 1.5 cell cycle lengths after treatment; second, 24 hr later	
TG 478 (Rodent dominant lethal):	1-5 daily	8 (mouse) or 10 (rat) weekly matings following last treatment	
	28 daily	4 (mouse) weekly matings following last treatment	
TG 483 (Mammalian spermatogonial chromosome aberration):	Single	Highest dose: 2x, 24 and 48 hr after treatment Other doses: 1x, 24 hr after treatment	
	Extended regimens can be used (e.g. 28 daily)	Same as for single treatment	
TG 488 (transgenic rodent somatic and germ cell gene mutation):	28 daily	Somatic tissues: 3 days following last treatment: however, for slowly dividing tissues longer sampling times (e.g. 28 days) may be used. Germ Cells: seminiferous tubule cells, 3 days; sperm: 49 days (mouse); 70 days (rats).	
TG 489 (mammalian comet)	Single	2-6 hr and 16-26 hr after treatment	
	2 or more daily	2-6 hr after treatment	

APPENDIX C. COMPILATION OF PUBLISHED NEGATIVE (VEHICLE) CONTROL DATA FOR THE DOMINANT LETHAL TEST

Female Strain	Male Strain	No. of Females	Total implantations	Total Resorptions	% Resorptions	St Dev	Reference
(101xC3H)F1	(101xC3H)F1	331	2441	189	7.7	3.0	Generoso <i>et al.</i> (1982)
(101xC3H)F1	(101xC3H)F1	294	3366	267	7.9	1.3	Ehling & Neuhauser-Klaus (1989)
(101xC3H)F1	(101xC3H)F1	540	5830	581	10.0	1.0	Ehling & Neuhauser-Klaus (1988)
(101xC3H)F1	(101xC3H)F1	169	1266	117	9.3	2.4	Ehling <i>et al.</i> (1968)
(101xC3H)F1	(101xC3H)F1	304	2123	148	7.0	3.3	Generoso <i>et al.</i> (1975)
(101xC3H)F1	(101xC3H)F1	506	5375	490	9.1	1.1	Ehling (1971)
(101xC3H)F1	(101xC3H)F1	438	4774	414	8.7	0.7	Ehling (1974)
Total or Mean		2582	25175	2206	8.8¹	1.1	
(102xC3H)F1	(102xC3H)F1	116	1221	98	8.0	2.8	Adler <i>et al.</i> (1998a)
(102xC3H)F1	(102xC3H)F1	494	5467	466	8.5	1.6	Adler <i>et al.</i> (2002)
(102xC3H)F1	(102xC3H)F1	349	3965	359	9.0	1.7	Ehling & Neuhauser-Klaus (1995)
(102xC3H)F1	(102xC3H)F1	353	4059	350	8.6	1.2	Ehling & Neuhauser-Klaus (1995)
(102xC3H)F1	(102xC3H)F1	229	2665	257	9.6	2.2	Adler <i>et al.</i> (1995)
(102xC3H)F1	(102xC3H)F1	449	4938	393	8.0	1.9	Ehling & Neuhauser-Klaus (1994)
(102xC3H)F1	(102xC3H)F1	341	3921	403	10.3	1.9	Ehling & Neuhauser-Klaus (1991)
(102xC3H)F1	(102xC3H)F1	589	6528	525	8.0	1.3	Ehling & Neuhauser-Klaus (1991)
Total or Mean		2920	32764	2851	8.7¹	0.8	
(C3Hx101)F1	(C3Hx101)F1	90	704	44	6.3	1.5	Shelby <i>et al.</i> (1986)
(C3Hx101)F1	(101xC3H)F1	50	407	34	8.5	2.2	Generoso <i>et al.</i> (1982)
Total or Mean		140	1111	78	7.0¹	1.6	
(C3HxC57BL)F1	(101xC3H)F1	67	713	47	6.6	0.9	Generoso <i>et al.</i> (1982)
BALB/c	BALB/c	24	181	54	29.8	10.1	Lovell <i>et al.</i> (1987)
BALB/c	BALB/c	60	562	25	4.4	1.2	Blaszowska (2010)
Total		84	347	79	nd	nd	
B6CF1	Various	129	1296	71	5.5	4.3	Bishop <i>et al.</i> (1983)
B6C3F1	Various	128	1224	53	4.3	1.2	Bishop <i>et al.</i> (1983)
B6C3F1	(101xC3H)F1	388	4340	183	4.2	2.0	Witt <i>et al.</i> (2003)
B6C3F1	(101xC3H)F1	91	957	46	4.6	0.1	Witt <i>et al.</i> (2003)
B6C3F1	(101xC3H)F1	168	1855	89	4.8	0.6	Sudman <i>et al.</i> (1992)
B6C3F1	B6C3F1	290	2846	134	3.1	1.7	Kligerman <i>et al.</i> (1994)
Total or Mean		1065	11222	505	4.5¹	0.7	
CBB6F1	CBB6F1	45	461	45	9.8	4.6	Lovell <i>et al.</i> (1987)
CBA/Ca	CBA/Ca	24	198	23	11.6	1.1	Lovell <i>et al.</i> (1987)

C57BL/6J	DBA/2J	129	1115	67	6.0	3.1	Barnett <i>et al.</i> (1992)
C57BL/6J	DBA/2J	199	1832	118	6.4	2.6	Barnett & Lewis (2003)
C57BL/6J	C57BL/6J	42	329	52	15.8 ¹	na	Rao <i>et al.</i> (1994)
Total or Mean		370	3276	237	7.2¹	5.5	Rao <i>et al.</i> (1994)
CD-1	CD-1	46	572	37	6.5	na	Anderson <i>et al.</i> (1998)
CD-1	B6C3F1	178	1983	131	6.6	3.1	Dunnick <i>et al.</i> (1984)
CD-1	CD-1	na	na	na	3.6	0.7	Guo <i>et al.</i> (2005)
CD-1	CD-1	447	5217	299	5.7	1.7	Anderson <i>et al.</i> (1976a)
CD-1	CD-1	323	4035	289	7.2	0.7	Anderson <i>et al.</i> (1976b)
CD-1	CD-1	702	8575	523	6.1	0.9	Anderson <i>et al.</i> (1977)
Total or Mean		1696	20382	1279	6.3¹	1.3	
(SECxC57BL)F1	(C3Hx101)F1	39	359	8	2.2	na	Shelby <i>et al.</i> (1986)
(SECxC57BL)F1	(C3Hx101)F1	733	7098	260	3.7	2.3	Generoso <i>et al.</i> (1995)
(SECxC57BL)F1	(C3Hx101)F1	613	5883	198	3.4	1.3	Generoso <i>et al.</i> (1986)
(SECxC57BL)F1	(C3Hx101)F1	386	4021	115	2.9	1.1	Generoso <i>et al.</i> (1996)
(SECxC57BL)F1	(C3Hx101)F1	288	2969	91	3.1	1.3	Shelby <i>et al.</i> (1991)
(SECxC57BL)F1	(101xC3H)F1	50	514	20	4.0	1.5	Generoso <i>et al.</i> (1982)
(SECxC57BL)F1	(101xC3H)F1	200	2111	55	2.6	1.7	Sudman <i>et al.</i> (1992)
Total or Mean		2311	22955	747	3.3¹	0.6	
NMRI	(102xC3H)F1	103	1535	93	6.1	1.3	Adler <i>et al.</i> (1998)
NMRI	NMRI	137	1692	83	4.9	0.5	Lang & Adler (1977)
Total or Mean		240	3227	176	5.5¹	0.8	
Swiss Albino	Swiss Albino	243	2693	282	10.5	1.3	Attia (2012)
Swiss Albino	Swiss Albino	243	2672	274	10.3	1.0	Attia (2012)
Swiss Albino	Swiss Albino	322	3541	357	10.1	1.3	Attia <i>et al.</i> (2015)
Total or Mean		808	8906	913	10.1¹	0.2	
Swiss	Swiss	275	2804	164	5.8	1.2	Rao <i>et al.</i> (1994)
Swiss	C57BL	71	722	32	4.4	1.7	Rao <i>et al.</i> (1994)
Swiss	CBA	76	710	26	3.7	2.5	Rao <i>et al.</i> (1994)
Total or Mean		422	4236	222	3.7¹	1.1	
T-Stock	(CH3x101)F1	755	6851	1125	16.4	3.1	Shelby <i>et al.</i> (1986)
T-Stock	(CH3x101)F1	822	7713	935	12.1	2.6	Generoso <i>et al.</i> (1995)
T-Stock	(CH3x101)F1	323	3116	472	15.2	2.6	Shelby <i>et al.</i> (1991)
Total or Mean		1900	17680	2532	14.3¹	2.2	

¹ weighted mean
na: not available
nd: not determined

**APPENDIX D. COMPILATION OF PUBLISHED NEGATIVE (VEHICLE) CONTROL DATA
FOR THE MOUSE SPERMATOGONIAL CHROMOSOMAL ABERRATION TEST.**

No. of mice	Strain	No. of cells	No of aberration/cell x 100					No. of aberrations/cell x 100 (excluding gaps)	% aberrant cells (excluding gaps)	Ref.
			Gaps	Chromatid type		Chromosome type				
				Breaks	Exchanges	Breaks	Exchanges			
24	(101x C3H)F1	1600	0.56	0.13	0	0	0	0.13	0.13	Adler, 1982
28	(101x C3H)F1	1400	0.79	0.14	0	0	0	0.14	0.14	Adler, 1982
10	(101x C3H)F1	20,000	0.63	0.14	0.005	0	0	0.15	0.15	Adler, 1982
4	(101x C3H)F1	400	0	0	0	0	0	0	0	Adler, 1982
35	(101 x C3H)F1	1750	0.97	0.11	0	0	0	0.11	0.11	Adler, 1974
6	CD1	700	NR	0.54	0	0	0	0.54	NR	Luippold <i>et al.</i> 1978
1	CBA	300	NR	0.33	0	0	0	0.33	0.33	Tates and Natarajan, 1976
2	Swiss	250	NR	0	0	0	0	0	0	vanBuur and Goudzwaard, 1980
6	(101 x C3H)F1	600	6.0	0.5	0	0	0	0.50	0.5	Adler and El-Tarras, 1989
6	(102 x C3H)F1	600	5.0	0.83	0	0	0	0.83	0.83	Ciranni and Adler, 1991
20	Balb/c	2000	0.05	0.05	0	0	0	0.05	0.05	Hu and Zu, 1990
5	Kun-Ming	250	0	0.4	0	0	0	0.40	0.4	Zhang <i>et al.</i> , 1998
7	Kun-Ming	350	0.29	0.29	0	0	0	0.29	0.29	Zhang <i>et al.</i> , 2008
6	Swiss	274	3.65	1.46	0	0	0	1.46	1.46	* Palo <i>et al.</i> , 2011; Palo <i>et al.</i> , 2009, Palo <i>et al.</i> , 2005
5	Swiss	1000	4.9	1.20	0	0	0	1.20	1.20	Ciranni <i>et al.</i> , 1991
6	NMRI	300	0.33	0.33	0	0	0	0.33	0.33	Rathenberg, 1975
8	(101 x C3H)F1	800	0	0	0	0	0	0	0	Miltenburger, et al. 1978
6	A-AJAX	560	0.90	0	0	0	0	0	0	Miltenburger, et al. 1978
32	NMRI	3200	0.34	0.13	0	0	0	0.13	0.13	Miltenburger, et al. 1978

* These three papers report the same control data. NR: Not reported

APPENDIX E. DEFINITIONS

Administration period: the total period during which an animal is dosed.

Aneugen: any chemical or process that, by interacting with the components of the mitotic and meiotic cell division cycle, leads to aneuploidy in cells or organisms.

Aneuploidy: any deviation from the normal diploid (or haploid) number of chromosomes by a single chromosome or more than one, but not by entire set(s) of chromosomes (polyploidy).

Apoptosis: programmed cell death triggered by DNA damage and characterised by a series of steps leading to the disintegration of cells into membrane-bound particles that are then eliminated by phagocytosis or by shedding.

Base pair substitution: a gene mutation characterised by the substitution of one base pair for another in the DNA.

Cell proliferation: the increase in cell number as a result of mitotic cell division. Reduction in cell proliferation is generally considered a marker of cytotoxicity, a key parameter in genotoxicity assays.

Centromere: the DNA region of a chromosome where both chromatids are held together and on which both kinetochores are attached side-to-side.

Chromatid-type aberration: structural chromosome damage expressed as breakage of single chromatids or breakage and reunion between chromatids.

Chromosome-type aberration: structural chromosome damage expressed as breakage, or breakage and reunion, of both chromatids at an identical site.

Clastogen: a chemical that causes structural chromosomal aberrations in populations of cells or organisms.

Clonal expansion: the production by cell division of many cells from a single (mutant) cell.

Cloning efficiency: the percentage of cells plated in a mammalian cell assay which are able to grow into a colony that can be counted.

Comet: the shape that nucleoids adopt after submitted to one electrophoretic field; the head is the nucleus and the tail is constituted by the DNA migrating out of the nucleus in the electric field. The shape resembles a comet.

Cytogenetic assay: a test that detects damage to chromosomes (i.e. cytogenetic damage) either as chromosome anomalies *per se* that can be visualised microscopically at metaphase (i.e. TGs 473, 475, 483), or as micronuclei that can be detected microscopically, or with flow cytometry, (i.e. TGs 474, 487). Chromosomal aberrations include breaks in chromosomes that result in deletion, duplication or rearrangement of chromosome segments, or a change (gain or loss) in chromosome number (i.e. aneuploidy).

Cytokinesis: the process of cell division immediately following mitosis to form two daughter cells, each containing a single nucleus.

Cytokinesis-block proliferation index (CBPI): a measure of cell proliferation consisting of the proportion of second-division cells in the treated population relative to the untreated control.

Cytotoxicity: cytotoxicity is defined for each specific test (see individual TGs).

Deletion: a gene mutation in which one or more (sequential) nucleotides is lost from the genome, or a chromosomal aberration in which a portion of a chromosome is lost.

Dominant lethal mutation: a mutation occurring in a germ cell, or is fixed after fertilisation, that causes embryonic or foetal death.

Endoreduplication: a process in which after an S period of DNA replication, the nucleus does not go into mitosis but starts another S period. The result is chromosomes with 4, 8, 16, ...chromatids.

Erythroblast: an early stage of erythrocyte development, preceding the immature erythrocyte, where the cell still contains a nucleus.

Fertility rate: the number of mated pregnant females expressed in relationship to the number of mated females.

Forward mutation: a gene mutation from the parental type to the mutant form which gives rise to an alteration of the activity or the function of the encoded protein.

Frameshift mutation: a gene mutation characterised by the addition or deletion of single or multiple (different from three or multiples of three) base pairs in the DNA molecule.

Gap: an achromatic lesion smaller than the width of one chromatid, and with minimum misalignment of the chromatids.

Gene mutation assay: a test that detects heritable (to daughter cells or organisms) alterations to the gene specific to the particular assay. These alterations can either activate or inactivate the specific gene. Gene mutation include changes in a single or multiple nucleotide base pairs which can be substitution of one base for another or addition or deletion of one or more bases in the base pair sequence and in some assays, the deletion of the entire gene.

Genotoxicity: a general term encompassing all types of DNA or chromosomal damage, including DNA strand breaks, adducts, rearrangements, mutations, structural chromosome aberrations, and aneuploidy. Not all types of genotoxic effects result in mutations or stable (transmissible) chromosomal damage.

Insertion: a gene mutation characterised by the addition of one or more nucleotide base pairs into a DNA sequence.

Interphase cells: cells not in the mitotic stage.

Kinetochore: a protein-containing structure that assembles at the centromere of a chromosome to which spindle fibers associate during cell division, allowing orderly movement of daughter chromosomes to the poles of the daughter cells.

Mating interval: the time between the end of exposure and mating of treated males. By controlling this interval, chemical effects on different germ cell types can be assessed. Effects originating in testicular

sperm, condensed spermatids, round spermatids, pachytene spermatocytes, early spermatocytes, dividing spermatogonia, and stem cell spermatogonia are detected by using mating intervals of different lengths.

Micronuclei: small fragments of or an entire nuclear chromosome, separate from and in addition to the main nuclei of cells, produced during telophase of mitosis (meiosis) by lagging chromosome fragments or whole chromosomes.

Mitogen: a chemical that stimulates a cell to commence cell division, triggering mitosis (*i.e.* cell division).

Mitotic index: a measure of the proliferation status of a cell population consisting of the ratio of the number of cells in mitosis to the total number of cells in a population.

Mitosis: division of the cell nucleus usually divided into prophase, prometaphase, metaphase, anaphase and telophase.

Mitotic recombination: A type of genetic recombination that occurs in somatic cells during their preparation for mitosis. Mitotic recombination between homologous alleles can result in loss of heterozygosity (LOH) which is an important genetic event during human tumorigenesis.

Mutagen: a chemical that induces genetic events that alter the DNA and/or chromosomal structure or number and that are passed to subsequent generations.

Mutagenicity: a subset of genotoxicity. Mutagenicity results in events that alter the DNA and/or chromosomal number or structure that are irreversible and, therefore, capable of being passed to subsequent cell generations if they are not lethal to the cell in which they occur. Thus, mutations include the following: 1) changes in a single base pairs; partial, single or multiple genes; or chromosomes; 2) breaks in chromosomes that result in the stable (transmissible) deletion, duplication or rearrangement of chromosome segments; 3) a change (gain or loss) in chromosome number (*i.e.* aneuploidy) resulting in cells that have not an exact multiple of the haploid number; and, 4) DNA changes resulting from mitotic recombination.

Mutant frequency (MF): the number of mutant colonies observed divided by the number of cells plated in selective medium, corrected for cloning efficiency (or viability) at the time of selection.

Mutation frequency: the frequency of independently generated mutations. Generally calculated as the number of observed independent mutations divided by the number of cells that are evaluated for the presence of mutations. In the context of the TGs it is used for the transgenic mutation assays in which mutants are sequenced and the mutant frequency is corrected based on the number of mutants found to be siblings (from clonal expansion).

Normochromatic or mature erythrocyte: a fully matured erythrocyte that has lost the residual RNA that remains after enucleation and/or has lost other short-lived cell markers that characteristically disappear after enucleation following the final erythroblast division.

Numerical chromosome aberration: a chromosomal aberration consisting of a change in the number of chromosomes from the normal number characteristic of the animals utilised (aneuploidy).

Phenotypic expression time: the time after treatment during which the genetic alteration is fixed within the genome and any preexisting gene products are depleted to the point that the phenotypic trait is altered and, therefore, can be enumerated using a selective drug or procedure.

Polychromatic or immature erythrocyte (PCE): a newly formed erythrocyte in an intermediate stage of development, which does not contain a nucleus. It stains with both the blue and red components of classical blood stains such as Wright's giemsa because of the presence of residual RNA in the newly-formed cell. Such newly formed cells are approximately the same as reticulocytes, which are visualised using a vital stain that causes the residual RNA to clump into a reticulum. Other methods, including monochromatic staining of RNA with fluorescent dyes or labeling of short-lived surface markers such as CD71 with fluorescent antibodies, are now often used to identify the immature erythrocyte. Polychromatic erythrocytes, reticulocytes, and CD71-positive erythrocytes are all immature erythrocytes, though each has a somewhat different developmental distribution.

Polyploidy: a numerical chromosomal abnormality consisting of a change in the number of the entire set(s) of chromosomes, as opposed to a numerical change in part of the chromosome set (*cf.* aneuploidy).

Reticulocyte: a newly formed erythrocyte stained with a vital stain that causes residual cellular RNA to clump into a characteristic reticulum. Reticulocytes and polychromatic erythrocytes have a similar cellular age distribution.

Relative cell counts (RCC): measure of cell proliferation that is the ratio of the final cell count of the treated culture compared to the final cell count of the control cultures expressed as a percentage. Revised TGs do not include this as an acceptable measure of cytotoxicity.

Relative increase in cell count (RICC): a measure of cell proliferation that is the ratio of the increase in number of cells in treated cultures (final – starting) compared to the increase in the number of cells in the control cultures (final - starting) expressed as a percentage.

Relative population doubling (RPD): a measure of cell proliferation that is the ratio of number of population doublings in treated cultures (final – starting) compared to the number of population doublings in control cultures (final – starting) expressed as a percentage.

Relative survival (RS): a measure of treatment-related cytotoxicity; the cloning efficiency (CE) of cells plated immediately after treatment adjusted by any loss of cells during treatment compared with the cloning efficiency in negative controls (which are assigned a survival of 100%).

Relative Total growth (RTG): RTG is used as the measure of treatment-related cytotoxicity in the MLA. It reflects the relative (to the vehicle control) growth of test cultures during the, treatment, two-day expression and mutant selection cloning phases of the test. The relative suspension growth of each test culture is multiplied by the relative cloning efficiency of the test culture at the time of mutant selection to obtain the RTG.

Replication index (RI): a measure of cell proliferation consisting of the proportion of cell division cycles completed in a treated culture, relative to the untreated control, during the exposure period and recovery.

S9 mix: mix of the liver S9 fraction (supernatant of liver homogenate after 9000g centrifugation, *i.e.* raw liver extract.) and cofactors necessary for cytochrome P450 metabolic enzyme activity.

Solvent control: general term to define the negative control cultures receiving the solvent used to dissolve the test chemical.

Structural chromosomal aberration: a change in chromosome structure detectable by microscopic examination of the metaphase stage of cell division, observed as deletions and fragments, intrachanges or interchanges.

Untreated control: cultures that receive no treatment (*i.e.* neither test chemical nor solvent) but are processed concurrently and in the same way as the cultures receiving the test chemical.